{"id":12789,"date":"2026-02-19T18:18:00","date_gmt":"2026-02-19T18:18:00","guid":{"rendered":"https:\/\/csiag.eu\/?p=12789"},"modified":"2026-02-21T06:07:24","modified_gmt":"2026-02-21T06:07:24","slug":"immunsejt-terapia","status":"publish","type":"post","link":"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/","title":{"rendered":"Immunsejt-ter\u00e1pia"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_90 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Tartalomjegyz\u00e9k<\/p>\n<span class=\"ez-toc-title-toggle\"><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1' ><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Das_Immunsystem_%E2%80%93_was_macht_das\" >Az immunrendszer - mit csin\u00e1l?<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Was_Immunzelltherapie_macht\" >Mit tesz az immunsejtter\u00e1pia<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Das_Geniale_daran\" >A zsenialit\u00e1s<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Die_drei_Typen_%E2%80%93_ganz_einfach\" >A h\u00e1rom t\u00edpus - nagyon egyszer\u0171<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#T-Zellen_und_ihre_Rolle\" >T-sejtek \u00e9s szerep\u00fck<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Tumorimmunologie-Grundprinzip\" >A tumorimmunol\u00f3gia alapelvei<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#CAR-T-Zelltherapie_%E2%80%93_Konstruktion_und_Mechanismus\" >CAR-T sejtter\u00e1pia - tervez\u00e9s \u00e9s mechanizmus<\/a><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Molekularer_Aufbau_des_CAR\" >A CAR molekul\u00e1ris szerkezete<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Herstellungsprozess_Autolog\" >Gy\u00e1rt\u00e1si folyamat (Autologue)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Wirkmechanismus_Effektorphase\" >A hat\u00e1smechanizmus \u00e9s az effektor f\u00e1zis<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#TCR-T-Zelltherapie_Die_entscheidenden_Unterschiede\" >TCR-T sejtter\u00e1pia: a legfontosabb k\u00fcl\u00f6nbs\u00e9gek<\/a><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Warum_TCR_und_nicht_CAR_fur_intrazellulare_Antigene\" >Mi\u00e9rt TCR \u00e9s nem CAR az intracellul\u00e1ris antig\u00e9nekhez?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Struktur_des_therapeutischen_TCR\" >A ter\u00e1pi\u00e1s TCR szerkezete<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#TIL-Therapie_%E2%80%93_Prinzip_der_naturlichen_Tumorerkennung\" >TIL-ter\u00e1pia - a term\u00e9szetes tumorfelismer\u00e9s elve<\/a><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Biologische_Grundlage\" >Biol\u00f3giai alap<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Herstellungsprozess_Lifileucel\" >Gy\u00e1rt\u00e1si folyamat (Lifileucel)<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Herausforderungen_%E2%80%93_aktuelle_Forschungsansatze\" >Kih\u00edv\u00e1sok - jelenlegi kutat\u00e1si megk\u00f6zel\u00edt\u00e9sek<\/a><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Antigen-Escape\" >Antig\u00e9n menek\u00fcl\u00e9s<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#T-Zell-Erschopfung_Exhaustion\" >T-sejt kimer\u00fcl\u00e9s (kimer\u00fcl\u00e9s)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Tumormikroumgebung_TME\" >Tumoros mikrok\u00f6rnyezet (TME)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Zytokinsturm_CRS_ICANS\" >Citokin vihar (CRS) \u00e9s ICANS<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Allogene_%E2%80%9EOff-the-shelf%E2%80%9C-Therapien\" >Allog\u00e9n \u201ek\u00e9sz\u201c ter\u00e1pi\u00e1k<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#27_Quantitative_Wirksamkeitsdaten_im_Uberblick\" >2.7 A mennyis\u00e9gi hat\u00e9konys\u00e1gi adatok \u00e1ttekint\u00e9se<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Weiterfuhrende_Literatur_Ressourcen\" >Tov\u00e1bbi olvasnival\u00f3k \u00e9s forr\u00e1sok<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Weltweit_zugelassene_Immunzelltherapien\" >Vil\u00e1gszerte enged\u00e9lyezett immunsejtes ter\u00e1pi\u00e1k<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Einleitung_Die_drei_grosen_Klassen\" >Bevezet\u00e9s: A h\u00e1rom f\u0151 oszt\u00e1ly<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#CAR-T-ZELLTHERAPIEN\" >CAR-T SEJTTER\u00c1PI\u00c1K<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Tisagenlecleucel_Kymriah%C2%AE_%E2%80%93_Novartis\" >Tisagenlecleucel (Kymriah\u00ae) - Novartis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Axicabtagene_Ciloleucel_Yescarta%C2%AE_%E2%80%93_KiteGilead\" >Axicabtagene ciloleucel (Yescarta\u00ae) - Kite\/Gilead<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-30\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Brexucabtagene_Autoleucel_Tecartus%C2%AE_%E2%80%93_KiteGilead\" >Brexucabtagene Autoleucel (Tecartus\u00ae) - Kite\/Gilead<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-31\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Lisocabtagene_Maraleucel_Breyanzi%C2%AE_%E2%80%93_Bristol_Myers_Squibb\" >Lisocabtagene Maraleucel (Breyanzi\u00ae) - Bristol Myers Squibb<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-32\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Idecabtagene_Vicleucel_Abecma%C2%AE_%E2%80%93_Bristol_Myers_Squibb_2seventy_bio\" >Idecabtagene Vicleucel (Abecma\u00ae) - Bristol Myers Squibb \/ 2seventy bio<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-33\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Ciltacabtagene_Autoleucel_Carvykti%C2%AE_%E2%80%93_JanssenLegend_Biotech\" >Ciltacabtagene Autoleucel (Carvykti\u00ae) - Janssen\/Legend Biotech<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-34\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Obecabtagene_Autoleucel_Aucatzyl%C2%AE_%E2%80%93_Autolus_neu_112024\" >Obecabtagene Autoleucel (Aucatzyl\u00ae) - Autolus (\u00faj: 11.2024)<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-35\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#WELTWEIT_ZUGELASSEN_%E2%80%93_NICHT_IN_USAEU_weitere_Lander\" >Megengedett vil\u00e1gszerte - az USA-ban\/EU-ban (m\u00e1s orsz\u00e1gokban) nem)<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-36\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#China_NMPA_%E2%80%93_vier_zusatzliche_CAR-T-Produkte\" >K\u00edna (NMPA) - n\u00e9gy tov\u00e1bbi CAR-T term\u00e9k<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-37\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Indien_CDSCO\" >India (CDSCO)<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-38\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#TCR-T-ZELLTHERAPIEN_zugelassen\" >TCR-T CELL TER\u00c1PI\u00c1K (enged\u00e9lyezett)<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-39\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Afamitresgene_Autoleucel_Tecelra%C2%AE_%E2%80%93_Adaptimmune_August_2024\" >Afamitresgene Autoleucel (Tecelra\u00ae) - Adaptimmune (2024. augusztus)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-40\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Tebentafusp-tebn_Kimmtrak%C2%AE_%E2%80%93_Immunocore_Januar_2022\" >Tebentafusp-tebn (Kimmtrak\u00ae) - Immunocore (2022. janu\u00e1r)<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-41\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#TIL-THERAPIE_zugelassen\" >TIL-TER\u00c1PIA (enged\u00e9lyezett)<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-42\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Lifileucel_Amtagvi%C2%AE_%E2%80%93_Iovance_Biotherapeutics_Februar_2024\" >Lifileucel (Amtagvi\u00ae) - Iovance Biotherapeutics (2024. febru\u00e1r)<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-43\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Ubersicht_aller_Immunzelltherapien_weltweit\" >A vil\u00e1gszerte alkalmazott immunsejtes ter\u00e1pi\u00e1k \u00e1ttekint\u00e9se<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-44\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Nebenwirkungen_%E2%80%93_Was_alle_Therapien_verbindet\" >Mell\u00e9khat\u00e1sok - mi a k\u00f6z\u00f6s a ter\u00e1pi\u00e1kban?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-45\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Wo_werden_diese_Therapien_in_Deutschland_angeboten\" >Hol k\u00edn\u00e1lj\u00e1k ezeket a ter\u00e1pi\u00e1kat N\u00e9metorsz\u00e1gban?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-46\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Ausblick_Was_kommt_als_nachstes\" >Kil\u00e1t\u00e1sok: Mi a k\u00f6vetkez\u0151 l\u00e9p\u00e9s?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-47\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#GKV-Erstattung_von_Immunzelltherapien_in_Deutschland\" >Az immunsejtter\u00e1pi\u00e1k SHI-visszat\u00e9r\u00edt\u00e9se N\u00e9metorsz\u00e1gban<\/a><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-48\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#CAR-T-Zelltherapien\" >CAR-T sejtter\u00e1pi\u00e1k<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-49\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#AMNOG_NUB-Verfahren\" >AMNOG \u00e9s NUB elj\u00e1r\u00e1s<\/a><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-50\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Fruhe_Nutzenbewertung_durch_den_G-BA\" >A G-BA \u00e1ltal v\u00e9gzett korai haszon\u00e9rt\u00e9kel\u00e9s<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-51\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Preisverhandlung_nach_%C2%A7_130b_SGB_V\" >\u00c1rat\u00e1rgyal\u00e1s az SGB V 130b \u00a7-a szerint<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-52\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#NUB-Verfahren_fur_Krankenhauser\" >NUB-elj\u00e1r\u00e1s k\u00f3rh\u00e1zak sz\u00e1m\u00e1ra<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-53\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Die_Realitat_Einzelfallantrage_und_Burokratie\" >A val\u00f3s\u00e1g: egyedi k\u00e9relmek \u00e9s b\u00fcrokr\u00e1cia<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-54\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Das_%E2%80%9EPay-for-Outcome%E2%80%9C-Modell\" >A \u201efizet\u00e9s az eredm\u00e9ny\u00e9rt\u201c modell<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-55\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Welche_CAR-T-Produkte_sind_in_Deutschland_erstattungsfahig\" >Mely CAR-T term\u00e9kek jogosultak visszat\u00e9r\u00edt\u00e9sre N\u00e9metorsz\u00e1gban?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-56\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Kimmtrak_Tebentafusp_%E2%80%93_Sonderfall\" >Kimmtrak (Tebentafusp) - k\u00fcl\u00f6nleges eset<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-57\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#TIL-Therapie_Lifileucel_Amtagvi_%E2%80%93_In_Deutschland_derzeit_NICHT_erstattungsfahig\" >TIL-ter\u00e1pia (Lifileucel \/ Amtagvi) - N\u00e9metorsz\u00e1gban jelenleg NEM t\u00e9r\u00edthet\u0151 meg<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-58\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#TCR-T-Therapien_Afami-cel_Tecelra_%E2%80%93_In_Europa_nicht_zugelassen\" >TCR-T ter\u00e1pi\u00e1k (Afami-cel \/ Tecelra) - Eur\u00f3p\u00e1ban nem enged\u00e9lyezett.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-59\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Was_tun_wenn_die_Kasse_ablehnt_Rechtliche_Moglichkeiten\" >Mi a teend\u0151, ha a biztos\u00edt\u00f3 elutas\u00edtja? Jogi lehet\u0151s\u00e9gek<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-60\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Osterreich\" >Ausztria<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-61\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Schweiz\" >Sv\u00e1jc<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-62\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Zusammenfassung\" >\u00d6sszefoglal\u00f3<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-63\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#PKV_und_Immunzelltherapie_%E2%80%93_Die_vollstandige_Rechtslage\" >PKV \u00e9s immunsejtter\u00e1pia - a teljes jogi helyzet<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-64\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Das_rechtliche_Fundament_%C2%A7_192_VVG_und_MBKK_2009\" >A jogalap: VVG 192. \u00a7 \u00e9s MB\/KK 2009<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-65\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Der_Schlusselbegriff_%E2%80%9EMedizinisch_notwendige_Heilbehandlung%E2%80%9C\" >A kulcssz\u00f3: \u201eorvosilag sz\u00fcks\u00e9ges kezel\u00e9s\u201c.\u201c<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-66\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Das_Richtungsurteil_OLG_Frankfurt_29062022_%E2%80%93_Az_7_U_14021\" >A m\u00e9rf\u00f6ldk\u0151nek sz\u00e1m\u00edt\u00f3 \u00edt\u00e9let: OLG Frankfurt, 29.06.2022 - Ref. 7 U 140\/21.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-67\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Das_%E2%80%9Eauffallige_Missverhaltnis%E2%80%9C_nach_%C2%A7_192_Abs_2_VVG_%E2%80%93_und_warum_es_bei_CAR-T_nicht_greift\" >A VVG 192. \u00a7 (2) bekezd\u00e9se szerinti \u201efelt\u0171n\u0151 ar\u00e1nytalans\u00e1g\u201c - \u00e9s hogy mi\u00e9rt nem vonatkozik a CAR-T-re<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-68\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Das_Voranfrageverfahren_nach_%C2%A7_192_Abs_8_VVG_%E2%80%93_der_wichtigste_praktische_Schritt\" >A VVG 192. \u00a7 (8) bekezd\u00e9se szerinti el\u0151zetes vizsg\u00e1lati elj\u00e1r\u00e1s - a legfontosabb gyakorlati l\u00e9p\u00e9s<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-69\" href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/#Bei_Ablehnung_Rechtsmittel_und_Klage\" >Elutas\u00edt\u00e1s eset\u00e9n: fellebbez\u00e9s \u00e9s jogi elj\u00e1r\u00e1s<\/a><\/li><\/ul><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<span class=\"span-reading-time rt-reading-time\" style=\"display: block;\"><span class=\"rt-label rt-prefix\">Olvas\u00e1si id\u0151<\/span> <span class=\"rt-time\"> 20<\/span> <span class=\"rt-label rt-postfix\">percek<\/span><\/span>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Das_Immunsystem_%E2%80%93_was_macht_das\"><\/span>Az immunrendszer - mit csin\u00e1l?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Az immunrendszer egy eg\u00e9sz sereg felder\u00edt\u0151t, harcost tart fenn (<em>T-sejtek<\/em>) \u00e9s seg\u00edt\u0151k. Folyamatosan j\u00e1r\u0151r\u00f6znek a szervezetben, \u00e9s keresik a betolakod\u00f3kat, p\u00e9ld\u00e1ul a bakt\u00e9riumokat, v\u00edrusokat, de a szervezet saj\u00e1t, elvadult sejtjeit - a r\u00e1kos sejteket - is.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Norm\u00e1lis esetben az ilyen tombol\u00f3 sejteket az immunrendszer \u0151rz\u0151i gyorsan felismerik, elpuszt\u00edtj\u00e1k, maradv\u00e1nyaikat elt\u00e1vol\u00edtj\u00e1k \u00e9s lebontj\u00e1k. Ez nap mint nap folyamatosan t\u00f6rt\u00e9nik. Ily m\u00f3don a legt\u00f6bb r\u00e1kos sejtet az immunrendszer megakad\u00e1lyozza a terjed\u00e9sben, \u00e9s id\u0151ben \u00e1rtalmatlann\u00e1 teszi.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A r\u00e1kos sejtek azonban tal\u00e1l\u00e9konyak, mivel minden\u00e1ron t\u00fal akarnak \u00e9lni. Ez\u00e9rt \u00e1lc\u00e1zz\u00e1k magukat, hat\u00e9konyan elb\u00fajnak az immunrendszer \u0151rei el\u0151l, \u00e9s szinte akad\u00e1lytalanul terjednek tov\u00e1bb. Nemcsak felismerhetetlenn\u00e9 teszik magukat, mint ellens\u00e9get, hanem az immunrendszert is annyira lefoglalj\u00e1k, hogy egy bizonyos id\u0151 ut\u00e1n kimer\u00fcl, \u00e9s ak\u00e1r ki is ny\u00fajthatja a sz\u00e1rnyait - \u00e9s megadhatja mag\u00e1t a r\u00e1knak.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Was_Immunzelltherapie_macht\"><\/span>Mit tesz az immunsejtter\u00e1pia<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Az immunsejtter\u00e1pi\u00e1ban az immunsejteket kiveszik a betegb\u0151l, jobb felismer\u00e9si technol\u00f3gi\u00e1val, nagyobb harci er\u0151vel vagy \u00faj \u201ec\u00e9loptik\u00e1val\u201c l\u00e1tj\u00e1k el, \u00e9s visszahelyezik a szervezetbe, ahol c\u00e9lzottabban t\u00e1madhatj\u00e1k \u00e9s puszt\u00edthatj\u00e1k el a r\u00e1kot.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Das_Geniale_daran\"><\/span>A zsenialit\u00e1s<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">A kemoter\u00e1pi\u00e1val ellent\u00e9tben, amely elvileg mindent elpuszt\u00edt, ami gyorsan oszt\u00f3dik (egyr\u00e9szt a r\u00e1kos sejteket, de - akaratlanul - a hajsejteket, b\u00e9lsejteket stb. is), az immunsejtter\u00e1pi\u00e1k a k\u00f6vetkez\u0151 c\u00e9lpontokat veszik c\u00e9lba <strong>csak a r\u00e1kos sejteken<\/strong> - legal\u00e1bbis elm\u00e9letben.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Mivel az immunrendszer eml\u00e9kszik az \u00e1ltala felismert ellens\u00e9gekre, azonnal megt\u00e1madja az \u00faj r\u00e1kos sejteket, \u00e9s elpuszt\u00edtja \u0151ket, ha a r\u00e1k visszat\u00e9rne. Ez a magyar\u00e1zata annak, hogy egyes betegek egyetlen inf\u00fazi\u00f3 ut\u00e1n tart\u00f3san tumormentesek maradnak.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Die_drei_Typen_%E2%80%93_ganz_einfach\"><\/span>A h\u00e1rom t\u00edpus - nagyon egyszer\u0171<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>1 CAR-T sejtek: A konverzi\u00f3<\/strong><br>A T-sejteket (az immunrendszer harci erej\u00e9t) veszik, \u00e9s laborat\u00f3riumban egy teljesen \u00faj \u201emarkol\u00f3 kart\u201c, egy mesters\u00e9ges receptort \u00e9p\u00edtenek bel\u00e9j\u00fck. Ez felismeri a r\u00e1kos sejtek felsz\u00edn\u00e9nek egy nagyon speci\u00e1lis tulajdons\u00e1g\u00e1t, majd k\u00f6zvetlen\u00fcl elpuszt\u00edtja a r\u00e1kos sejtet.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>2 TCR T-sejtek: A jobb szem\u00fcveg<\/strong><br>A CAR-T-hez hasonl\u00f3an a T-sejt mesters\u00e9ges markol\u00f3 kar helyett egy tov\u00e1bbfejlesztett term\u00e9szetes receptort kap, amely szint\u00e9n felismeri azokat a jellemz\u0151ket, amelyek m\u00e9lyen a szervezetben vannak. <em>a  weboldalon bel\u00fcl<\/em> a r\u00e1kos sejtet, \u00e9s csak apr\u00f3 t\u00f6red\u00e9kek l\u00e1that\u00f3k k\u00edv\u00fclr\u0151l.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>3. TIL ter\u00e1pia: A veter\u00e1n<\/strong><br>Itt olyan T-sejteket vesznek, amelyek m\u00e1r <em>mag\u00e1ban a tumorban<\/em> \u00e9s ismerd meg \u0151t. Kivonj\u00e1k \u0151ket, laborat\u00f3riumban t\u00f6megesen szapor\u00edtj\u00e1k - n\u00e9h\u00e1ny sejtb\u0151l milli\u00e1rdok lesznek -, \u00e9s visszak\u00fcldik a tapasztalt \u201eveter\u00e1noknak\u201c.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"T-Zellen_und_ihre_Rolle\"><\/span>T-sejtek \u00e9s szerep\u00fck<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Az adapt\u00edv immunrendszer k\u00e9t f\u0151 sejtt\u00edpuson alapul: <strong>B-sejtek<\/strong> (ellenanyag-termel\u00e9s) \u00e9s <strong>T-sejtek<\/strong> (sejtes immunit\u00e1s). A T-sejtek, amelyek k\u00e9t funkcion\u00e1lis popul\u00e1ci\u00f3ra oszlanak, els\u0151sorban az \u00f6sszes immunsejtes ter\u00e1pia szempontj\u00e1b\u00f3l relev\u00e1nsak:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>CD8+ citotoxikus T-sejtek (CTL)<\/strong><br>T-sejt-receptorukon (TCR) kereszt\u00fcl felismerik a fert\u0151z\u00f6tt vagy rosszindulat\u00fa sejtek felsz\u00edn\u00e9n l\u00e9v\u0151 peptid-MHC I. oszt\u00e1ly\u00fa komplexeket, \u00e9s perforin\/granzim B felszabadul\u00e1s vagy FasL\/Fas k\u00f6lcs\u00f6nhat\u00e1s r\u00e9v\u00e9n apopt\u00f3zist induk\u00e1lnak.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>CD4+ seg\u00edt\u0151 T-sejtek<\/strong><br>Koordin\u00e1lj\u00e1k az immunv\u00e1laszt a citokinszekr\u00e9ci\u00f3 (IL-2, IFN-\u03b3, TNF-\u03b1) r\u00e9v\u00e9n, \u00e9s elengedhetetlenek a CTL-v\u00e1lasz hossz\u00fa t\u00e1v\u00fa fennmarad\u00e1s\u00e1hoz.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Tudom\u00e1nyos alap:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Alapvet\u0151 munka a T-sejt immunol\u00f3gi\u00e1val kapcsolatban: <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK10757\/\" target=\"_blank\" rel=\"noopener\">Janeway immunbiol\u00f3gi\u00e1ja (NCBI k\u00f6nyvespolc)<\/a><\/li>\n\n\n\n<li>A T-sejtek kimer\u00fcl\u00e9s\u00e9nek \u00e1ttekint\u00e9se a r\u00e1kban: <a href=\"https:\/\/www.nature.com\/articles\/nri3862\" target=\"_blank\" rel=\"noopener\">Wherry &amp; Kurachi, Nature Reviews Immunology 2015<\/a><\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Tumorimmunologie-Grundprinzip\"><\/span>A tumorimmunol\u00f3gia alapelvei<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">A r\u00e1k nem immunol\u00f3giai v\u00e1kuumban alakul ki. A <strong>R\u00e1k Immunoediting<\/strong>-koncepci\u00f3 (Dunn, Bruce &amp; Schreiber, 2004) h\u00e1rom f\u00e1zist \u00edr le:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Kik\u00fcsz\u00f6b\u00f6l\u00e9s<\/strong><br>Az immunrendszer a tumorhoz kapcsol\u00f3d\u00f3 antig\u00e9nek (TAA) \u00e9s tumorspecifikus antig\u00e9nek (TSA) seg\u00edts\u00e9g\u00e9vel ismeri fel \u00e9s puszt\u00edtja el az \u00e1talakult sejteket. A mut\u00e1ns peptidek MHC-I \u00e1ltal k\u00f6zvet\u00edtett prezent\u00e1ci\u00f3ja aktiv\u00e1lja a CTL-t.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Egyens\u00falyi \u00e1llapot<\/strong><br>Az immunrendszer egyens\u00falyban tartja a tumor n\u00f6veked\u00e9s\u00e9t, ugyanakkor szelekt\u00e1l az immunrezisztens v\u00e1ltozatok k\u00f6z\u00f6tt.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Menek\u00fcl\u00e9s<\/strong><br>A r\u00e1kos sejtek az MHC-I downregul\u00e1ci\u00f3ja, az immunellen\u0151rz\u00e9si pontok (PD-L1, CTLA-4 ligand\u00e1k) t\u00falreprezent\u00e1ci\u00f3ja, az immunszuppressz\u00edv citokinek (TGF-\u03b2, IL-10) szekr\u00e9ci\u00f3ja \u00e9s a szab\u00e1lyoz\u00f3 T-sejtek (Tregek) toborz\u00e1sa r\u00e9v\u00e9n menek\u00fclnek.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Tudom\u00e1nyos alap:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/www.cell.com\/immunity\/fulltext\/S1074-7613(02)00272-3\" target=\"_blank\" rel=\"noopener\">Dunn et al, Immunity 2002<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.cell.com\/immunity\/fulltext\/S1074-7613(13)00272-X\" target=\"_blank\" rel=\"noopener\">Chen &amp; Mellman, Immunity 2013 - Cancer Immunity Cycle (R\u00e1k immunit\u00e1s ciklusa)<\/a><\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"CAR-T-Zelltherapie_%E2%80%93_Konstruktion_und_Mechanismus\"><\/span>CAR-T sejtter\u00e1pia - tervez\u00e9s \u00e9s mechanizmus<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Molekularer_Aufbau_des_CAR\"><\/span>A CAR molekul\u00e1ris szerkezete<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">A kim\u00e9ra antig\u00e9nreceptor (CAR) egy szintetikus transzmembr\u00e1nfeh\u00e9rje n\u00e9gy funkcion\u00e1lis dom\u00e9nnel:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>1. extracellul\u00e1ris k\u00f6t\u0151 dom\u00e9n<\/strong><br>T\u00f6bbnyire egy <strong>scFv<\/strong> (egyl\u00e1nc\u00fa v\u00e1ltoz\u00f3 fragmentum) monoklon\u00e1lis antitest. K\u00f6zvetlen\u00fcl k\u00f6t\u0151dik egy felsz\u00edni antig\u00e9nhez (pl. CD19 a B-sejteken, BCMA a plazmasejteken) MHC-f\u00fcggetlen m\u00f3don. Ez az MHC-f\u00fcggetlens\u00e9g alapvet\u0151 k\u00fcl\u00f6nbs\u00e9g a term\u00e9szetes TCR-hez k\u00e9pest.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>2. csukl\u00f3\/\u00f6sszek\u00f6t\u0151 r\u00e9gi\u00f3<\/strong><br>Rugalmas t\u00e1vtart\u00f3 a k\u00f6t\u0151 dom\u00e9n \u00e9s a sejtmembr\u00e1n k\u00f6z\u00f6tt (pl. IgG4-Hinge, CD8\u03b1-Hinge). A hossz \u00e9s a rugalmass\u00e1g er\u0151sen befoly\u00e1solja a k\u00f6t\u00e9si hat\u00e9konys\u00e1got.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>3. transzmembr\u00e1n dom\u00e9n<\/strong><br>A CAR-t lehorgonyozza a T-sejtmembr\u00e1nban; befoly\u00e1solja a jel stabilit\u00e1s\u00e1t.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>4. intracellul\u00e1ris jel\u00e1tviteli dom\u00e9n<\/strong><br>Els\u0151dleges aktiv\u00e1ci\u00f3s dom\u00e9nb\u0151l (CD3\u03b6 3 ITAM-mal) + t\u00e1rs-stimul\u00e1l\u00f3 dom\u00e9nekb\u0151l \u00e1ll. A ko-stimul\u00e1l\u00f3 dom\u00e9nek hat\u00e1rozz\u00e1k meg a <strong>CAR gener\u00e1ci\u00f3:<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Gener\u00e1ci\u00f3<\/th><th>Co-stimul\u00e1ci\u00f3<\/th><th>Jellemz\u0151<\/th><\/tr><\/thead><tbody><tr><td>Gen 1<\/td><td>Csak CD3\u03b6<\/td><td>R\u00f6vid \u00e9let\u0171, gyenge prolifer\u00e1ci\u00f3<\/td><\/tr><tr><td>2. gener\u00e1ci\u00f3<\/td><td>CD28 <strong>vagy<\/strong> 4-1BB (CD137) + CD3\u03b6<\/td><td>Standard ma; Kymriah=4-1BB; Yescarta=CD28<\/td><\/tr><tr><td>3. gener\u00e1ci\u00f3<\/td><td>CD28 <strong>\u00e9s<\/strong> 4-1BB + CD3\u03b6<\/td><td>Er\u0151sebb aktiv\u00e1l\u00e1s, a CRS fokozott kock\u00e1zata<\/td><\/tr><tr><td>4. gener\u00e1ci\u00f3<\/td><td>2. g\u00e9n + transzg\u00e9n (pl. IL-12, IL-15)<\/td><td>\u201eArmored CAR\u201c, jav\u00edtott tumoros mikrok\u00f6rnyezet<\/td><\/tr><tr><td>5. gener\u00e1ci\u00f3<\/td><td>2. g\u00e9n + intracellul\u00e1ris IL-2R\u03b2 dom\u00e9n<\/td><td>Jagged-CAR; JAK-STAT jel\u00e1tviteli \u00fatvonal<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>4-1BB vs. CD28 t\u00e1rs-stimul\u00e1ci\u00f3<\/strong><br>A 4-1BB-CAR-ok (Kymriah) jobb hossz\u00fa t\u00e1v\u00fa perzisztenci\u00e1t \u00e9s kisebb kimer\u00fcl\u00e9st mutatnak (kisebb T-sejt-kimer\u00fcl\u00e9s), a CD28-CAR-ok (Yescarta) gyorsabb kezdeti aktiv\u00e1ci\u00f3t \u00e9s magasabb korai v\u00e1laszad\u00e1si ar\u00e1nyt mutatnak, de \u00e1ltal\u00e1ban r\u00f6videbb a v\u00e1lasz id\u0151tartama.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Tudom\u00e1nyos alap:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>\u00c9p\u00edt\u00e9si \u00e1ttekint\u00e9s CAR: <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMra1706169\" target=\"_blank\" rel=\"noopener\">June &amp; Sadelain, NEJM 2018<\/a><\/li>\n\n\n\n<li>4-1BB vs. CD28 \u00f6sszehasonl\u00edt\u00e1s: <a href=\"https:\/\/www.nature.com\/articles\/s41591-018-0087-0\" target=\"_blank\" rel=\"noopener\">Salter et al, Nature Medicine 2018<\/a><\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Herstellungsprozess_Autolog\"><\/span>Gy\u00e1rt\u00e1si folyamat (Autologue)<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Leukaferezis<\/strong><br>A mononukle\u00e1ris v\u00e9rsejtek gy\u0171jt\u00e9se a beteg v\u00e9r\u00e9b\u0151l 3-5 \u00f3r\u00e1n \u00e1t tart\u00f3 sejtszepar\u00e1ci\u00f3val.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>T-sejt aktiv\u00e1ci\u00f3<\/strong><br>Ex vivo stimul\u00e1ci\u00f3 anti-CD3\/anti-CD28 antitesttel bevont gy\u00f6ngy\u00f6kkel vagy rekombin\u00e1ns ligandumokkal; IL-2 \u00e9s IL-7\/IL-15 hozz\u00e1ad\u00e1sa a prolifer\u00e1ci\u00f3 el\u0151seg\u00edt\u00e9s\u00e9re.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>G\u00e9ntranszfer<\/strong><br>A CAR-g\u00e9n bevezet\u00e9se a k\u00f6vetkez\u0151kkel:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Lentivir\u00e1lis vektor<\/strong> (Kymriah, Breyanzi): Stabil integr\u00e1ci\u00f3 a gazdagenomba; hossz\u00fa t\u00e1v\u00fa expresszi\u00f3.<\/li>\n\n\n\n<li><strong>Gammaretrovir\u00e1lis vektor<\/strong> (Yescarta, Tecartus): Hasonl\u00f3, de nagyobb az inszerci\u00f3s mutagenezis kock\u00e1zata.<\/li>\n\n\n\n<li><strong>Transzpozon rendszerek \/ mRNS<\/strong> (k\u00eds\u00e9rleti): Nem integr\u00e1l\u00f3 alternat\u00edv\u00e1k<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>B\u0151v\u00edt\u00e9s<\/strong><br>A transzduk\u00e1lt sejtek szapor\u00edt\u00e1sa 7-14 nap alatt jellemz\u0151en 10\u2078-10\u2079 sejtre.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Min\u0151s\u00e9gellen\u0151rz\u00e9s<\/strong><br>A CAR-transzdukci\u00f3 hat\u00e9konys\u00e1g\u00e1nak, sterilit\u00e1s\u00e1nak, marad\u00e9k komponensek, T-sejt fenot\u00edpus, hat\u00e9konys\u00e1gi teszt vizsg\u00e1lata.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Kri\u00f3t\u00e1rol\u00e1s \u00e9s sz\u00e1ll\u00edt\u00e1s<\/strong><br>a kezel\u0151k\u00f6zpontba.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Limfodepl\u00e9ci\u00f3<\/strong><br>A beteg a CAR-T inf\u00fazi\u00f3 el\u0151tt 2-7 nappal kemoter\u00e1pi\u00e1ban r\u00e9szes\u00fcl (\u00e1ltal\u00e1ban fludarabin + ciklofoszfamid), hogy cs\u00f6kkentse a szervezet saj\u00e1t immunsejtjeinek sz\u00e1m\u00e1t \u00e9s \u201eteret\u201c hozzon l\u00e9tre (limfodepl\u00e9ci\u00f3s kondicion\u00e1l\u00e1s). Ez a l\u00e9p\u00e9s a homeosztatikus IL-7\/IL-15 jel\u00e1tvitel r\u00e9v\u00e9n jelent\u0151sen n\u00f6veli a CAR-T sejtek prolifer\u00e1ci\u00f3j\u00e1t \u00e9s perzisztenci\u00e1j\u00e1t.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Inf\u00fazi\u00f3<\/strong><br>CAR-T sejtek egyszeri intrav\u00e9n\u00e1s inf\u00fazi\u00f3ja.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>A tudom\u00e1ny m\u00f6g\u00f6tte:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Limfogyaszt\u00f3 mechanizmus: <a href=\"https:\/\/www.nature.com\/articles\/nm1263\" target=\"_blank\" rel=\"noopener\">Gattinoni et al, Nature Medicine 2005<\/a><\/li>\n\n\n\n<li>Termel\u00e9si \u00e1ttekint\u00e9s: <a href=\"https:\/\/www.cell.com\/molecular-therapy-family\/molecular-therapy\/fulltext\/S1525-0016(16)45462-1\" target=\"_blank\" rel=\"noopener\">Levine et al, Molecular Therapy 2017<\/a><\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wirkmechanismus_Effektorphase\"><\/span>A hat\u00e1smechanizmus \u00e9s az effektor f\u00e1zis<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Az inf\u00fazi\u00f3 ut\u00e1n a CAR-T sejtek felismerik a daganatsejteken l\u00e9v\u0151 c\u00e9lantig\u00e9nj\u00fcket, \u00e9s immunol\u00f3giai szinapszist hoznak l\u00e9tre: A CAR megk\u00f6ti az antig\u00e9nt \u2192 CD3\u03b6-ITAM-ok foszforil\u00e1l\u00f3dnak \u2192 ZAP-70\/Lck kin\u00e1z kaszk\u00e1d \u2192 NF-\u03baB, NFAT, AP-1 aktiv\u00e1ci\u00f3 \u2192 perforin\/granzim B felszabadul\u00e1s (direkt citol\u00edzis) + IFN-\u03b3, TNF-\u03b1 (citokin szekr\u00e9ci\u00f3).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">P\u00e1rhuzamosan: <strong>Bystander aktiv\u00e1l\u00e1s<\/strong> - a felszabadul\u00f3 citokinek m\u00e1s endog\u00e9n immunsejteket aktiv\u00e1lnak, \u00e9s citokinfelszabadul\u00e1si szindr\u00f3m\u00e1hoz (CRS) vezethetnek.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Tudom\u00e1ny:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>CAR-T hat\u00e1smechanizmus: <a href=\"https:\/\/www.science.org\/doi\/10.1126\/science.aam8871\" target=\"_blank\" rel=\"noopener\">Lim &amp; June, Tudom\u00e1ny 2017<\/a><\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"TCR-T-Zelltherapie_Die_entscheidenden_Unterschiede\"><\/span>TCR-T sejtter\u00e1pia: a legfontosabb k\u00fcl\u00f6nbs\u00e9gek<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Warum_TCR_und_nicht_CAR_fur_intrazellulare_Antigene\"><\/span>Mi\u00e9rt TCR \u00e9s nem CAR az intracellul\u00e1ris antig\u00e9nekhez?<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">A CAR-receptorok csak a <strong>Felsz\u00edni feh\u00e9rj\u00e9k<\/strong>. Mivel azonban a legt\u00f6bb tumorspecifikus antig\u00e9n intracellul\u00e1risan lokaliz\u00e1l\u00f3dik (transzkripci\u00f3s faktorok, metabolikus enzimek, r\u00e1kos her\u00e9k antig\u00e9njei, mint a PRAME, MAGE-A4), a CAR-T vak lenne ezekre a c\u00e9lpontokra.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A term\u00e9szetes TCR k\u00e9pes felismerni az intracellul\u00e1ris feh\u00e9rj\u00e9ket, mivel a sejtfeh\u00e9rj\u00e9ket folyamatosan felismeri a <strong>Proteasz\u00f3ma<\/strong> ~8-11 aminosav hossz\u00fas\u00e1g\u00fa peptidekk\u00e9 bomlanak le. Ezek a peptidek az endoplazmatikus retikulumban bomlanak le, hogy <strong>MHC I. oszt\u00e1ly\u00fa molekul\u00e1k (HLA az emberben)<\/strong> \u00e9s a sejtfelsz\u00ednre sz\u00e1ll\u00edtj\u00e1k. Ott az \u03b1\u03b2-TCR megk\u00f6ti \u0151ket, amely mechanizmus minden sejtmagv\u00fa testsejtben akt\u00edv.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>A TCR-ter\u00e1pia technikai kih\u00edv\u00e1sa<\/strong> a sz\u00fcks\u00e9ges HLA-korl\u00e1toz\u00e1s: egy term\u00e9szetes, nagy affinit\u00e1s\u00fa TCR csak egy adott HLA-all\u00e9l (pl. HLA-A*02:01, amely a kauk\u00e1zusi popul\u00e1ci\u00f3 kb. 40-50 %-j\u00e9n\u00e9l fordul el\u0151) kontextus\u00e1ban ismer fel egy adott peptidet. Ez azt jelenti, hogy a betegeknek egyszerre kell HLA-kompatibilisnek \u00e9s a c\u00e9lantig\u00e9n tekintet\u00e9ben tumorpozit\u00edvnak lenni\u00fck.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Struktur_des_therapeutischen_TCR\"><\/span>A ter\u00e1pi\u00e1s TCR szerkezete<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">A ter\u00e1pi\u00e1s TCR-ek t\u00f6bbnyire <strong>\u03b1\u03b2-TCR heterodimerek<\/strong>, ami:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Fage display vagy eg\u00e9r-humaniz\u00e1ci\u00f3 r\u00e9v\u00e9n kifejlesztett, rendk\u00edv\u00fcl magas affinit\u00e1s\u00fa (KD a pM tartom\u00e1nyban). A term\u00e9szetes TCR csak k\u00f6zepes affinit\u00e1s\u00fa (\u03bcM), mivel a t\u00fal nagy affinit\u00e1s autoimmunit\u00e1shoz vezetne.<\/li>\n\n\n\n<li>Az endog\u00e9n TCR-l\u00e1ncokkal val\u00f3 nem sz\u00e1nd\u00e9kos p\u00e1ros\u00edt\u00e1s ellen stabiliz\u00e1lva murin\u00e1lis szubsztit\u00faci\u00f3kkal vagy diszulfidhidakkal.<\/li>\n\n\n\n<li>lentivir\u00e1lis transzdukci\u00f3val a beteg saj\u00e1t T-sejtjeibe kell bejuttatni.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Tudom\u00e1ny:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>TCR-affinit\u00e1sm\u00e9rn\u00f6ks\u00e9g: <a href=\"https:\/\/www.jimmunol.org\/content\/180\/9\/6116\" target=\"_blank\" rel=\"noopener\">Robbins et al, Journal of Immunology 2008<\/a><\/li>\n\n\n\n<li>Mechanizmus \u00e1ttekint\u00e9se TCR-T: <a href=\"https:\/\/aacrjournals.org\/cancerimmunolres\/article\/7\/8\/1236\/469286\" target=\"_blank\" rel=\"noopener\">Dangaj et al, Cancer Immunology Research 2019<\/a><\/li>\n\n\n\n<li>MAGE-A4 TCR alap a Tecelra sz\u00e1m\u00e1ra: <a href=\"https:\/\/aacrjournals.org\/clincancerres\/article\/25\/24\/7537\/82286\" target=\"_blank\" rel=\"noopener\">Kageyama et al, Clin Cancer Research 2019<\/a><\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"TIL-Therapie_%E2%80%93_Prinzip_der_naturlichen_Tumorerkennung\"><\/span>TIL-ter\u00e1pia - a term\u00e9szetes tumorfelismer\u00e9s elve<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Biologische_Grundlage\"><\/span>Biol\u00f3giai alap<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">A tumorok immunsejtek \u00e1ltal infiltr\u00e1ltak, a <strong>tumorba besziv\u00e1rg\u00f3 limfocit\u00e1k (TIL)<\/strong>. Ezek a T-sejtek m\u00e1r felismert\u00e9k a daganatot, de az immunszuppressz\u00edv tumoros mikrok\u00f6rnyezet (TME) miatt gyakran kimer\u00fcltek, anergi\u00e1sak vagy t\u00fal kevesen vannak. A daganatban l\u00e9v\u0151 magas TIL-s\u0171r\u0171s\u00e9g sz\u00e1mos r\u00e1kt\u00edpusban jobb progn\u00f3zissal korrel\u00e1l.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A TIL-ter\u00e1pia \u00f6tlete (amelyet Steven Rosenberg dolgozott ki az NCI-ben, Bethesd\u00e1ban az 1980-as \u00e9vekben): Vegy\u00fck ezeket a m\u00e1r tumorspecifikus T-sejteket, szabad\u00edtsuk ki \u0151ket az immunszuppressz\u00edv k\u00f6rnyezetb\u0151l, ex vivo aktiv\u00e1ljuk \u00e9s szapor\u00edtsuk \u0151ket t\u00f6megesen, \u00e9s olyan nagy sz\u00e1mban juttassuk vissza \u0151ket, hogy a kimer\u00fcl\u00e9sre val\u00f3 hajlam ellen\u00e9re ter\u00e1pi\u00e1san hat\u00e1soss\u00e1 v\u00e1ljanak.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Herstellungsprozess_Lifileucel\"><\/span>Gy\u00e1rt\u00e1si folyamat (Lifileucel)<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Tumor kimetsz\u00e9se<\/strong><br>Legal\u00e1bb 1,5 cm\u00b3 tumorsz\u00f6vetet seb\u00e9szi \u00faton elt\u00e1vol\u00edtanak, \u00e9s azonnal feldolgozz\u00e1k a k\u00f6vetkez\u0151 c\u00e9lokra <a href=\"https:\/\/www.iovance.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">Iovance Biotherapeutics, Inc.<\/a> k\u00fcld\u00f6tt.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Kezdeti b\u0151v\u00edt\u00e9s (kb. 11 nap)<\/strong><br>A tumort mechanikusan \u00e9s enzimatikusan disszoci\u00e1lj\u00e1k; a TIL-t IL-2 jelenl\u00e9t\u00e9ben teny\u00e9sztik \u2192 Pre-REP (Pre-Rapid Expansion Protocol).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Gyors terjeszked\u00e9s (kb. 11 nap)<\/strong><br>A TIL-eket anti-CD3 antitestekkel (OKT3), besug\u00e1rzott allog\u00e9n PBMC-kkel (amelyek antig\u00e9nprezent\u00e1l\u00f3 sejtekk\u00e9nt m\u0171k\u00f6dnek) \u00e9s IL-2-vel kezelik a k\u00f6vetkez\u0151 ideig <strong>&gt;7,5 \u00d7 10\u2079 sejtek<\/strong> b\u0151v\u00fcl (n\u00e9h\u00e1ny milli\u00f3r\u00f3l milli\u00e1rdokra).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Limfodepl\u00e9ci\u00f3 \u00e9s inf\u00fazi\u00f3<\/strong><br>Azonos a CAR-T-vel: Flu\/Cy kondicion\u00e1l\u00e1s, majd egyszeri TIL inf\u00fazi\u00f3, majd IL-2 bead\u00e1sa a tov\u00e1bbi in vivo terjeszked\u00e9shez.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Id\u0151keret<\/strong><br>Kb. 22 napos termel\u00e9s; a daganat elt\u00e1vol\u00edt\u00e1s\u00e1t\u00f3l az inf\u00fazi\u00f3 bead\u00e1s\u00e1ig \u00f6sszesen kb. 6-7 h\u00e9t.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Tudom\u00e1ny:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Rosenberg \u00fatt\u00f6r\u0151 munk\u00e1ja: <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJM198812223192529\" target=\"_blank\" rel=\"noopener\">Rosenberg et al, NEJM 1988<\/a><\/li>\n\n\n\n<li>Lifileucel 2. f\u00e1zis\u00fa pivot\u00e1lis vizsg\u00e1lat (C-144-01): <a href=\"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.21.02179\" target=\"_blank\" rel=\"noopener\">Chesney et al, JCO 2022<\/a><\/li>\n\n\n\n<li>5 \u00e9ves nyomon k\u00f6vet\u00e9s: <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40699950\/\" target=\"_blank\" rel=\"noopener\">PubMed FDA j\u00f3v\u00e1hagy\u00e1si \u00f6sszefoglal\u00f3 2024<\/a><\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Herausforderungen_%E2%80%93_aktuelle_Forschungsansatze\"><\/span>Kih\u00edv\u00e1sok - jelenlegi kutat\u00e1si megk\u00f6zel\u00edt\u00e9sek<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Antigen-Escape\"><\/span>Antig\u00e9n menek\u00fcl\u00e9s<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>A probl\u00e9ma meghat\u00e1roz\u00e1sa<\/strong><br>A daganatos sejtek lecs\u00f6kkenthetik vagy elvesz\u00edthetik a c\u00e9lantig\u00e9n kifejez\u0151d\u00e9s\u00e9t. A CD19-CAR-T eset\u00e9ben az esetek 30-40 %-\u00e9ben CD19-negat\u00edv relapszus fordul el\u0151.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Megold\u00e1s<\/strong><br>Kett\u0151s c\u00e9lz\u00e1si strat\u00e9gi\u00e1k (CD19+CD22, BCMA+CD38), tandem CAR-ok, logikai kapu CAR-ok (\u00c9S kapu: k\u00e9t antig\u00e9nre van sz\u00fcks\u00e9g; NEM kapu: csak a v\u00e9d\u0151 antig\u00e9n n\u00e9lk\u00fcli sejteket puszt\u00edtj\u00e1k el).<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/www.nature.com\/articles\/nm.4164\" target=\"_blank\" rel=\"noopener\">Ruella et al, Nature Medicine 2016 (CD19-Escape)<\/a><\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"T-Zell-Erschopfung_Exhaustion\"><\/span>T-sejt kimer\u00fcl\u00e9s (kimer\u00fcl\u00e9s)<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>A probl\u00e9ma meghat\u00e1roz\u00e1sa<\/strong><br>A daganatos sejtek lecs\u00f6kkenthetik vagy elvesz\u00edthetik a c\u00e9lantig\u00e9n kifejez\u0151d\u00e9s\u00e9t. A CD19-CAR-T eset\u00e9ben az esetek 30-40 %-\u00e9ben CD19-negat\u00edv relapszus fordul el\u0151.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Kr\u00f3nikus antig\u00e9n expoz\u00edci\u00f3 \u2192 Kimer\u00fcl\u00e9si markerek expresszi\u00f3ja (PD-1, TIM-3, LAG-3, TOX transzkripci\u00f3s faktor) \u2192 funkci\u00f3veszt\u00e9s.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Megold\u00e1s:<\/strong> Ellen\u0151rz\u0151pont-g\u00e1tl\u00f3kkal val\u00f3 kombin\u00e1ci\u00f3, epigenetikus \u00e1tprogramoz\u00e1s TET2 ki\u00fct\u00e9ssel, \u00fajgener\u00e1ci\u00f3s CAR-tervek be\u00e9p\u00edtett ellen\u0151rz\u0151pont-blok\u00e1ddal.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/www.nature.com\/articles\/s41586-019-1546-z\" target=\"_blank\" rel=\"noopener\">Chen et al, Nature 2019 (TET2 knockdown)<\/a><\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Tumormikroumgebung_TME\"><\/span>Tumoros mikrok\u00f6rnyezet (TME)<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>A probl\u00e9ma meghat\u00e1roz\u00e1sa<\/strong><br>A daganatos sejtek lecs\u00f6kkenthetik vagy elvesz\u00edthetik a c\u00e9lantig\u00e9n kifejez\u0151d\u00e9s\u00e9t. A CD19-CAR-T eset\u00e9ben az esetek 30-40 %-\u00e9ben CD19-negat\u00edv relapszus fordul el\u0151.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A szolid tumorok ellens\u00e9ges mikrok\u00f6rnyezettel rendelkeznek: hipoxia, gl\u00fck\u00f3zhi\u00e1ny, immunszuppressz\u00edv citokinek (TGF-\u03b2, IL-10), Tregek, MDSC-k.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Megold\u00e1s<\/strong><br>P\u00e1nc\u00e9lozott CAR-ok IL-12\/IL-15\/IL-18 szekr\u00e9ci\u00f3val, PD-1-rezisztens CAR-ok, anti-VEGF-fel kombin\u00e1lva, helyi intratumor\u00e1lis injekci\u00f3k.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/www.nature.com\/articles\/s41598-017-10259-0\" target=\"_blank\" rel=\"noopener\">Yeku et al, Scientific Reports 2017 (P\u00e1nc\u00e9lozott CAR)<\/a><\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Zytokinsturm_CRS_ICANS\"><\/span>Citokin vihar (CRS) \u00e9s ICANS<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>A probl\u00e9ma meghat\u00e1roz\u00e1sa<\/strong><br>A CRS-t az aktiv\u00e1lt CAR-T \u00e9s makrof\u00e1gok massz\u00edv citokinfelszabadul\u00e1sa (IL-6, IFN-\u03b3, IL-1\u03b2) okozza. A s\u00falyos CRS (3-4. fokozat) intenz\u00edv ter\u00e1pi\u00e1t ig\u00e9nyel. Az ICANS (neurol\u00f3giai toxicit\u00e1s) az endot\u00e9l aktiv\u00e1ci\u00f3 \u00e9s a v\u00e9r-agy g\u00e1t diszfunkci\u00f3ja k\u00f6vetkezt\u00e9ben alakul ki.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Menedzsment<\/strong><br>Tocilizumab (IL-6R blokkol\u00e1s), kortikoszteroidok, anakinra (IL-1 blokkol\u00e1s); a korai beavatkoz\u00e1s jav\u00edtja az eredm\u00e9nyeket.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4116524\/\" target=\"_blank\" rel=\"noopener\">Lee et al, Blood 2014 - CRS oszt\u00e1lyoz\u00e1si rendszer<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.nature.com\/articles\/nrneurol.2018.138\" target=\"_blank\" rel=\"noopener\">Neelapu et al, Nature Reviews Neurology 2018 - ICANS<\/a><\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Allogene_%E2%80%9EOff-the-shelf%E2%80%9C-Therapien\"><\/span>Allog\u00e9n \u201ek\u00e9sz\u201c ter\u00e1pi\u00e1k<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>A probl\u00e9ma meghat\u00e1roz\u00e1sa<\/strong><br>A daganatos sejtek lecs\u00f6kkenthetik vagy elvesz\u00edthetik a c\u00e9lantig\u00e9n kifejez\u0151d\u00e9s\u00e9t. A CD19-CAR-T eset\u00e9ben az esetek 30-40 %-\u00e9ben CD19-negat\u00edv relapszus fordul el\u0151.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Az autol\u00f3g el\u0151\u00e1ll\u00edt\u00e1s 3-6 h\u00e9tig tart \u00e9s dr\u00e1ga (400 000-600 000 \u20ac).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Megold\u00e1s<\/strong><br>Allog\u00e9n CAR-T eg\u00e9szs\u00e9ges donorokb\u00f3l, az endog\u00e9n TCR (GvHD megel\u0151z\u00e9se) \u00e9s HLA komponensek (kil\u00f6k\u0151d\u00e9s megel\u0151z\u00e9se) CRISPR ki\u00fct\u00e9s\u00e9vel.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Jelenlegi adatok<\/strong><br>A CTX112 (CRISPR-allog\u00e9n CD19-CAR-T) az els\u0151 teljes remisszi\u00f3t mutatja CLL-ben az 1. f\u00e1zisban.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/www.science.org\/doi\/10.1126\/science.abb4845\" target=\"_blank\" rel=\"noopener\">Stadtmauer \u00e9s munkat\u00e1rsai, Science 2020 - CRISPR CAR-T 1. f\u00e1zis<\/a><\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"27_Quantitative_Wirksamkeitsdaten_im_Uberblick\"><\/span>2.7 A mennyis\u00e9gi hat\u00e9konys\u00e1gi adatok \u00e1ttekint\u00e9se<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Ter\u00e1pia<\/th><th>Jelz\u00e9s<\/th><th>ORR<\/th><th>CR-ar\u00e1ny<\/th><th>Medi\u00e1n OS<\/th><th>Forr\u00e1s<\/th><\/tr><\/thead><tbody><tr><td>Tisagenlecleucel<\/td><td>B-ALL gyermekgy\u00f3gy\u00e1szat<\/td><td>81 %<\/td><td>60 %<\/td><td>NR (63 % 12 h\u00f3napos korban)<\/td><td>NEJM 2018<\/td><\/tr><tr><td>Axicabtagene-cel<\/td><td>DLBCL 3. vonal<\/td><td>83 %<\/td><td>58 %<\/td><td>NR (74 % 12 h\u00f3napos korban)<\/td><td>NEJM 2017<\/td><\/tr><tr><td>Ciltacabtagene-cel<\/td><td>Mult. myeloma<\/td><td>98 %<\/td><td>78 %<\/td><td>NR (&gt;80 % 12 h\u00f3nap alatt)<\/td><td>Lancet 2021<\/td><\/tr><tr><td>Lifileucel<\/td><td>Melanoma<\/td><td>31,4 %<\/td><td>7,5 %<\/td><td>NR (49 % 24 h\u00f3napos korban)<\/td><td>JCO 2022<\/td><\/tr><tr><td>Afamitresgene-cel<\/td><td>Szinovi\u00e1lis szark\u00f3ma<\/td><td>43 %<\/td><td>4 %<\/td><td>16,4 h\u00f3nap<\/td><td>Lancet 2024<\/td><\/tr><tr><td>Tebentafusp<\/td><td>Uve\u00e1lis melanoma<\/td><td>9 % (ORR)<\/td><td>&lt;1 %<\/td><td>21,7 h\u00f3nap<\/td><td>NEJM 2021<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><em>(NR = nem teljes\u00fclt; OS* m\u00e9g nem teljes\u00fclt)<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">*<em>OS<\/em> (<em>Teljes t\u00fal\u00e9l\u00e9s<\/em>\u00a0) - pl. \u201e<em>medi\u00e1n OS 21,7<\/em>\u201e hogy a betegek fele 21,7 h\u00f3nap ut\u00e1n meghalt, a m\u00e1sik fele pedig m\u00e9g mindig \u00e9letben volt.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Weiterfuhrende_Literatur_Ressourcen\"><\/span>Tov\u00e1bbi olvasnival\u00f3k \u00e9s forr\u00e1sok<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>V\u00e9lem\u00e9nyek:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/www.science.org\/doi\/10.1126\/science.aar6711\" target=\"_blank\" rel=\"noopener\">June et al, Science 2018 - CAR-T ter\u00e1pia \u00e1ttekint\u00e9s<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/link.springer.com\/article\/10.1007\/s00428-019-02571-3\" target=\"_blank\" rel=\"noopener\">Rohaan et al, Virchows Arch 2019 - TIL ter\u00e1pia \u00e1ttekint\u00e9se<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.nature.com\/articles\/s41586-019-1840-9\" target=\"_blank\" rel=\"noopener\">Stadtmauer et al, Nature 2020 - Allog\u00e9n TCR\/CAR-T<\/a><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Ir\u00e1nyelvek \u00e9s adatb\u00e1zisok:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/clinicaltrials.gov\/search?term=CAR-T+OR+TIL+OR+TCR-T&amp;recency=5\" target=\"_blank\" rel=\"noopener\">ClinicalTrials.gov - az \u00f6sszes folyamatban l\u00e9v\u0151 immunsejtter\u00e1pi\u00e1s vizsg\u00e1lat<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.cancer.gov\/about-cancer\/treatment\/types\/immunotherapy\/t-cell-transfer-therapy\" target=\"_blank\" rel=\"noopener\">NCI - Immunter\u00e1pia \u00e1ttekint\u00e9s<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.dgho.de\/informationen\/stellungnahmen\/gute-wissenschaftliche-praxis\/car-t-zellen\" target=\"_blank\" rel=\"noopener\">N\u00e9met Hematol\u00f3giai T\u00e1rsas\u00e1g (DGHO) - CAR-T ter\u00e1pia<\/a><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Betegbar\u00e1t forr\u00e1sok (n\u00e9met\u00fcl):<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/www.krebshilfe.de\/informieren\/ueber-krebs\/therapie\/immuntherapie\/\" target=\"_blank\" rel=\"noopener\">Krebshilfe Deutschland - Immunter\u00e1pia magyar\u00e1zat<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.kitz-heidelberg.de\/forschungsprogramme\/zell-und-gentherapie\/\" target=\"_blank\" rel=\"noopener\">KiTZ Heidelberg - Betegek \u00e9s immunter\u00e1pia<\/a><\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><em>Kevesebb mint egy \u00e9vtized alatt az immunsejtter\u00e1pia k\u00eds\u00e9rleti koncepci\u00f3b\u00f3l standard klinikai ter\u00e1pi\u00e1v\u00e1 v\u00e1lt, \u00e9s az enged\u00e9lyezett term\u00e9kek \u00e9s javallatok sz\u00e1ma tov\u00e1bbra is gyorsan n\u00f6vekszik. Az arra alkalmas betegek sz\u00e1m\u00e1ra ez lehet az egyetlen potenci\u00e1lisan gy\u00f3gy\u00edt\u00f3 lehet\u0151s\u00e9g.<\/em><\/p>\n\n\n\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Weltweit_zugelassene_Immunzelltherapien\"><\/span>Vil\u00e1gszerte enged\u00e9lyezett immunsejtes ter\u00e1pi\u00e1k<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">\u00c1llapot 02.2026<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Einleitung_Die_drei_grosen_Klassen\"><\/span>Bevezet\u00e9s: A h\u00e1rom f\u0151 oszt\u00e1ly<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Ma az \u201eimmunsejtter\u00e1pia\u201c kifejez\u00e9s h\u00e1rom k\u00fcl\u00f6nb\u00f6z\u0151 term\u00e9kkateg\u00f3ri\u00e1t takar az onkol\u00f3giai kontextusban:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>1. CAR-T sejtter\u00e1pia<\/strong> (Kim\u00e9ra antig\u00e9nreceptor T-sejtek)<br>Genetikailag m\u00f3dos\u00edtott T-sejtek szintetikus felsz\u00edni receptorral, amely felismeri a sejtek felsz\u00edn\u00e9n l\u00e9v\u0151 tumorantig\u00e9neket. Az \u00f6sszes eddig enged\u00e9lyezett term\u00e9k CD19 vagy BCMA ellen ir\u00e1nyul, \u00e9s v\u00e9rr\u00e1kos megbeteged\u00e9sek eset\u00e9n enged\u00e9lyezett.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>2. TCR-T sejtter\u00e1pia<\/strong> (T-sejt receptoros T-sejtek)<br>Genetikailag m\u00f3dos\u00edtott T-sejtek, amelyek optimaliz\u00e1lt term\u00e9szetes T-sejt receptorral rendelkeznek, amely felismeri a HLA-komplexen megjelen\u0151 intracellul\u00e1ris tumorfeh\u00e9rj\u00e9ket. El\u0151sz\u00f6r 2024-ben enged\u00e9lyezik szolid tumorok kezel\u00e9s\u00e9re.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>3. TIL ter\u00e1pia<\/strong> (tumorba besziv\u00e1rg\u00f3 limfocit\u00e1k)<br>Nem genetikailag m\u00f3dos\u00edtott T-sejtek, amelyeket a beteg daganat\u00e1b\u00f3l nyernek, t\u00f6megesen szapor\u00edtanak \u00e9s \u00fajra beadagolnak. El\u0151sz\u00f6r 2024-ben enged\u00e9lyezik melan\u00f3ma kezel\u00e9s\u00e9re.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">2024 december\u00e9ig az FDA hat CAR-T-sejtes ter\u00e1pi\u00e1t hagyott j\u00f3v\u00e1, \u00e9s vil\u00e1gszerte t\u00edz CAR-T-sejtes ter\u00e1pia volt kereskedelmi forgalomban. Ezen k\u00edv\u00fcl van egy TIL-ter\u00e1pia (Lifileucel) \u00e9s egy TCR-ter\u00e1pia (Afamitresgene autoleucel) - az els\u0151 a kateg\u00f3ri\u00e1jukban szil\u00e1rd daganatok eset\u00e9ben. <a href=\"https:\/\/www.curemelanoma.org\/blog\/melanoma-clinical-trials-to-watch-fall-2025\" target=\"_blank\" rel=\"noreferrer noopener\">MRA<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"CAR-T-ZELLTHERAPIEN\"><\/span>CAR-T SEJTTER\u00c1PI\u00c1K<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Tisagenlecleucel_Kymriah%C2%AE_%E2%80%93_Novartis\"><\/span>Tisagenlecleucel (Kymriah\u00ae) - <em>Novartis<\/em><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>C\u00e9lzott antig\u00e9n:<\/strong> CD19 <br><strong>Enged\u00e9lyezve:<\/strong> FDA 2017 \/ EMA 2018<br><strong>Az els\u0151 vil\u00e1gszerte enged\u00e9lyezett CAR-T term\u00e9k<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Jelz\u00e9sek<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Gyermekek \u00e9s fiatal feln\u0151ttek 25 \u00e9ves korig: relapszusos\/refrakteri\u00e1lis B-sejtes ALL (akut limfoblasztos leuk\u00e9mia).<\/li>\n\n\n\n<li>Feln\u0151ttek: relapszus\/refrakteri\u00e1lis nagy B-sejtes limf\u00f3ma (LBCL) \u22652 sziszt\u00e9m\u00e1s ter\u00e1pia ut\u00e1n.<\/li>\n\n\n\n<li>Relapszusos\/refrakteri\u00e1lis follikul\u00e1ris limf\u00f3ma (FL)<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>A legfontosabb tanulm\u00e1nyok<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>ELIANA tanulm\u00e1ny (ALL gyermekgy\u00f3gy\u00e1szat): <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT02435849\" target=\"_blank\" rel=\"noopener\">NCT02435849<\/a> | <a href=\"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.21.01019\" target=\"_blank\" rel=\"noopener\">JCO 2021<\/a><\/li>\n\n\n\n<li>JULIET tanulm\u00e1ny (LBCL): <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT02445248\" target=\"_blank\" rel=\"noopener\">NCT02445248<\/a><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Enged\u00e9lyez\u0151 hat\u00f3s\u00e1gok<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>FDA<\/li>\n\n\n\n<li>EMA<\/li>\n\n\n\n<li>TGA (Ausztr\u00e1lia)<\/li>\n\n\n\n<li>PMDA (Jap\u00e1n) <\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Gy\u00e1rt\u00f3\/Webhely:<\/strong> <a href=\"https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/kymriah.pdf\" target=\"_blank\" rel=\"noopener\">Novartis Kymriah<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>FDA term\u00e9koldal:<\/strong> <a href=\"https:\/\/www.fda.gov\/vaccines-blood-biologics\/kymriah\" target=\"_blank\" rel=\"noopener\">FDA Kymriah<\/a><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Axicabtagene_Ciloleucel_Yescarta%C2%AE_%E2%80%93_KiteGilead\"><\/span>Axicabtagene Ciloleucel (Yescarta\u00ae) - <em>Kite\/Gilead<\/em><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>C\u00e9lzott antig\u00e9n:<\/strong> CD19<br><strong>Enged\u00e9lyezve:<\/strong> FDA 2017 okt\u00f3ber \/ EMA 2018 augusztus<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Jelz\u00e9sek<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Nagy B-sejtes limf\u00f3ma (DLBCL, PMBCL, HGBCL, tFL) \u22652 sziszt\u00e9m\u00e1s ter\u00e1pia ut\u00e1n.<\/li>\n\n\n\n<li>Primer refrakter DLBCL vagy relapszus 12 h\u00f3napon bel\u00fcl (2. vonal)<\/li>\n\n\n\n<li>Relapszusos\/refrakteri\u00e1lis follikul\u00e1ris limf\u00f3ma \u22652 sziszt\u00e9m\u00e1s ter\u00e1pia ut\u00e1n<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>A legfontosabb tanulm\u00e1nyok<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>ZUMA-1 (LBCL, ORR 82 %): <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT02348216\" target=\"_blank\" rel=\"noopener\">NCT02348216<\/a> | <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1707447\" target=\"_blank\" rel=\"noopener\">NEJM 2017<\/a><\/li>\n\n\n\n<li>ZUMA-7 (2. vonal vs. ASCT): <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT03391466\" target=\"_blank\" rel=\"noopener\">NCT03391466<\/a><\/li>\n\n\n\n<li>ZUMA-5 (follikul\u00e1ris limf\u00f3ma, ORR &gt;90 %): <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT03105336\" target=\"_blank\" rel=\"noopener\">NCT03105336<\/a><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Kezel\u0151k\u00f6zpontok (D\/A\/CH kiv\u00e1laszt\u00e1s)<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Minden min\u0151s\u00edtett, FACT\/JACIE \u00e1ltal akkredit\u00e1lt transzplant\u00e1ci\u00f3s k\u00f6zpont; N\u00e9metorsz\u00e1gban pl.: University Medical Centre Hamburg-Eppendorf, Charit\u00e9 Berlin, LMU Klinikum M\u00fcnchen, University Medical Centre Heidelberg.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Gy\u00e1rt\u00f3\/Honlap<\/strong>: <a href=\"https:\/\/www.yescarta.com\" target=\"_blank\" rel=\"noopener\">Gilead Yescarta<\/a><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Brexucabtagene_Autoleucel_Tecartus%C2%AE_%E2%80%93_KiteGilead\"><\/span>Brexucabtagene Autoleucel (Tecartus\u00ae) - <em>Kite\/Gilead<\/em><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>C\u00e9lzott antig\u00e9n:<\/strong> CD19<br><strong>Enged\u00e9lyezve:<\/strong> FDA 2020. j\u00falius (MCL), 2021. okt\u00f3ber (ALL feln\u0151tt) \/ EMA 2020. december<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Jelz\u00e9sek<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>BTK-g\u00e1tl\u00f3t k\u00f6vet\u0151en relapsz\u00e1lt\/refrakteri\u00e1lis k\u00f6penysejtes limf\u00f3ma (MCL)<\/li>\n\n\n\n<li>Feln\u0151ttek relapszusban\/refrakteri\u00e1lis B-sejtes ALL-ben szenved\u0151 betegek<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>A legfontosabb tanulm\u00e1nyok<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>ZUMA-2 (MCL, OS 12 h\u00f3nap: 83 %): <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT02601313\" target=\"_blank\" rel=\"noopener\">NCT02601313<\/a><\/li>\n\n\n\n<li>ZUMA-3 (feln\u0151tt B-ALL, OS medi\u00e1n 18,2 h\u00f3nap): <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT02614066\" target=\"_blank\" rel=\"noopener\">NCT02614066<\/a><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>FDA term\u00e9koldal:<\/strong> <a href=\"https:\/\/www.fda.gov\/vaccines-blood-biologics\/tecartus\" target=\"_blank\" rel=\"noopener\">FDA Tecartus<\/a><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Lisocabtagene_Maraleucel_Breyanzi%C2%AE_%E2%80%93_Bristol_Myers_Squibb\"><\/span>Lisocabtagene Maraleucel (Breyanzi\u00ae) - <em>Bristol Myers Squibb<\/em><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>C\u00e9lzott antig\u00e9n:<\/strong> CD19<br><strong>Enged\u00e9lyezve:<\/strong> FDA 2021. febru\u00e1r 2021 (kezdeti) \/ kiterjesztett indik\u00e1ci\u00f3k 2022-2024 \/ EMA 2022. okt\u00f3ber 2022<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Jelz\u00e9sek<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Nagy B-sejtes limf\u00f3ma (LBCL, DLBCL, HGBCL, FL) 2. + 3. vonalban<\/li>\n\n\n\n<li>Kr\u00f3nikus limfocita leuk\u00e9mia (CLL) \/ kissejtes limfocita limf\u00f3ma (SLL) \u22652 ter\u00e1pia ut\u00e1n, bele\u00e9rtve a BTK-g\u00e1tl\u00f3t is (FDA 2024).<\/li>\n\n\n\n<li>Follikul\u00e1ris limf\u00f3ma (FL) \u22652 sziszt\u00e9m\u00e1s ter\u00e1pia ut\u00e1n<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>A legfontosabb tanulm\u00e1nyok<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>TRANSFORM (2. vonalbeli DLBCL): <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT03575351\" target=\"_blank\" rel=\"noopener\">NCT03575351<\/a><\/li>\n\n\n\n<li>TRANSCEND-CLL-004 (CLL\/SLL): <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT03331198\" target=\"_blank\" rel=\"noopener\">NCT03331198<\/a> | <a href=\"https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(24)00422-7\/fulltext\" target=\"_blank\" rel=\"noopener\">Lancet 2024<\/a><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>FDA term\u00e9koldal:<\/strong> <a href=\"https:\/\/www.fda.gov\/vaccines-blood-biologics\/breyanzi\" target=\"_blank\" rel=\"noopener\">FDA Breyanzi<\/a><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Idecabtagene_Vicleucel_Abecma%C2%AE_%E2%80%93_Bristol_Myers_Squibb_2seventy_bio\"><\/span>Idecabtagene Vicleucel (Abecma\u00ae) - <em>Bristol Myers Squibb \/ 2seventy bio<\/em><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>C\u00e9lzott antig\u00e9n:<\/strong> BCMA (B-sejt \u00e9r\u00e9si antig\u00e9n)<br><strong>Enged\u00e9lyezve:<\/strong> FDA 2021. m\u00e1rcius \/ EMA 2021. augusztus<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Jelz\u00e9s<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Relapszusos\/refrakteri\u00e1lis myeloma multiplex \u22654 kor\u00e1bbi ter\u00e1pi\u00e1s vonal ut\u00e1n<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>A legfontosabb tanulm\u00e1ny<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>KarMMa tanulm\u00e1ny (ORR 73 %): <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT03361748\" target=\"_blank\" rel=\"noopener\">NCT03361748<\/a> | <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2024850\" target=\"_blank\" rel=\"noopener\">NEJM 2021<\/a><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>FDA term\u00e9koldal:<\/strong> <a href=\"https:\/\/www.fda.gov\/vaccines-blood-biologics\/abecma\" target=\"_blank\" rel=\"noopener\">FDA Abecma<\/a><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Ciltacabtagene_Autoleucel_Carvykti%C2%AE_%E2%80%93_JanssenLegend_Biotech\"><\/span>Ciltacabtagene Autoleucel (Carvykti\u00ae) - <em>Janssen\/Legend Biotech<\/em><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>C\u00e9lzott antig\u00e9n:<\/strong> BCMA (kett\u0151s k\u00f6t\u0151d\u00e9s\u0171)<br><strong>Enged\u00e9lyezve:<\/strong> FDA 2022 febru\u00e1r (\u22654 vonal), meghosszabb\u00edtva 2024 \u00e1prilis (\u22651 vonal) \/ EMA 2022 m\u00e1jus<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>K\u00fcl\u00f6nlegess\u00e9g:<\/strong> Egyed\u00fcl\u00e1ll\u00f3 kett\u0151s antitestes CAR k\u00e9t BCMA-k\u00f6t\u0151 egydom\u00e9nes antitesttel; az eddigi leghat\u00e9konyabb enged\u00e9lyezett myeloma ter\u00e1pi\u00e1nak sz\u00e1m\u00edt.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Jelz\u00e9sek<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Relapszusos\/refrakteri\u00e1lis myeloma multiplex \u22654 ter\u00e1pi\u00e1s sort k\u00f6vet\u0151en<\/li>\n\n\n\n<li>2024 \u00e1prilisa \u00f3ta (FDA): \u22651 ter\u00e1pi\u00e1s vonal ut\u00e1n lenalidomid-refrakter betegs\u00e9g eset\u00e9n.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>A legfontosabb tanulm\u00e1nyok<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>CARTITUDE-1 (ORR 98 %, CR 78 %): <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT03548207\" target=\"_blank\" rel=\"noopener\">NCT03548207<\/a> | <a href=\"https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(21)00933-4\/fulltext\" target=\"_blank\" rel=\"noopener\">Lancet 2021<\/a><\/li>\n\n\n\n<li>CARTITUDE-4 (3. f\u00e1zis, az 1. visszaes\u00e9s meghosszabb\u00edt\u00e1sa): <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04181827\" target=\"_blank\" rel=\"noopener\">NCT04181827<\/a><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>FDA term\u00e9koldal:<\/strong> <a href=\"https:\/\/www.fda.gov\/vaccines-blood-biologics\/carvykti\" target=\"_blank\" rel=\"noopener\">FDA Carvykti<\/a><br><strong>Gy\u00e1rt\u00f3:<\/strong> <a href=\"https:\/\/www.carvykti.com\" target=\"_blank\" rel=\"noopener\">carvykti.com<\/a><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Obecabtagene_Autoleucel_Aucatzyl%C2%AE_%E2%80%93_Autolus_neu_112024\"><\/span>Obecabtagene Autoleucel (Aucatzyl\u00ae) - <em>Autolus<\/em> <em>(\u00faj: 11.2024)<\/em><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>C\u00e9lzott antig\u00e9n:<\/strong> CD19 (gyors lefoly\u00e1s\u00fa kialak\u00edt\u00e1s - alacsonyabb toxicit\u00e1s, mint az el\u0151dj\u00e9n\u00e9l)<br><strong>Enged\u00e9lyezve:<\/strong> FDA 2024. november 8.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Jelz\u00e9s<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Feln\u0151ttek relapszusban\/refrakteri\u00e1lis B-sejtes ALL-ben szenved\u0151 betegek<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>K\u00fcl\u00f6nlegess\u00e9g:<\/strong> Az els\u0151 CAR-T term\u00e9k, amelyet REMS-program (kock\u00e1zat\u00e9rt\u00e9kel\u00e9si \u00e9s kock\u00e1zatcs\u00f6kkent\u00e9si strat\u00e9gia) n\u00e9lk\u00fcl hagytak j\u00f3v\u00e1; a biztons\u00e1goss\u00e1g javul\u00e1s\u00e1nak \u00e9s az \u00faj CD19-k\u00f6t\u00e9si koncepci\u00f3nak a jele.<br><a href=\"https:\/\/www.dasgelbeblatt.de\/welt\/immunzelltherapie-heilt-ueberraschend-krebs-bei-einem-jugendlichen-zr-94168662.html\" target=\"_blank\" rel=\"noreferrer noopener\">A s\u00e1rga lev\u00e9l<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>A legfontosabb tanulm\u00e1ny<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>FELIX vizsg\u00e1lat (1\/2 f\u00e1zis, CR ar\u00e1ny 42 % 3 h\u00f3nap alatt): <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04404660\" target=\"_blank\" rel=\"noopener\">NCT04404660<\/a><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>FDA term\u00e9koldal:<\/strong> <a href=\"https:\/\/www.fda.gov\/vaccines-blood-biologics\/aucatzyl\" target=\"_blank\" rel=\"noopener\">FDA Aucatzyl<\/a><br><strong>Gy\u00e1rt\u00f3:<\/strong> <a href=\"https:\/\/www.autolus.com\" target=\"_blank\" rel=\"noopener\">autolus.com<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"WELTWEIT_ZUGELASSEN_%E2%80%93_NICHT_IN_USAEU_weitere_Lander\"><\/span>Megengedett vil\u00e1gszerte - az USA-ban\/EU-ban (m\u00e1s orsz\u00e1gokban) nem)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"China_NMPA_%E2%80%93_vier_zusatzliche_CAR-T-Produkte\"><\/span>K\u00edna (NMPA) - n\u00e9gy tov\u00e1bbi CAR-T term\u00e9k<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Vil\u00e1gszerte \u00f6sszesen tizenegy autol\u00f3g CAR-T-sejtes ter\u00e1pia kapta meg a kezdeti enged\u00e9lyt. Hetet az FDA, n\u00e9gyet pedig a k\u00ednai NMPA, mindegyiket relapszusos\/refrakteri\u00e1lis hematol\u00f3giai malignit\u00e1sok kezel\u00e9s\u00e9re.<br><a href=\"https:\/\/ucla.clinicaltrials.researcherprofiles.org\/trial\/NCT06743126\" target=\"_blank\" rel=\"noreferrer noopener\">Immatics US, Inc.<\/a><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Kereskedelmi n\u00e9v<\/th><th>Akt\u00edv \u00f6sszetev\u0151<\/th><th>C\u00e9lzott antig\u00e9n<\/th><th>Jelz\u00e9s<\/th><th>Enged\u00e9lyez\u00e9s<\/th><\/tr><\/thead><tbody><tr><td>Carteyva<\/td><td>Relmacabtagene autoleucel<\/td><td>BCMA<\/td><td>Mult. Myeloma, DLBCL<\/td><td>NMPA 2021\/2023<\/td><\/tr><tr><td>Fucaso<\/td><td>Equecabtagene autoleucel<\/td><td>BCMA<\/td><td>Mult. myeloma<\/td><td>NMPA 2023<\/td><\/tr><tr><td>Yuanruida<\/td><td>Satricabtagene autoleucel<\/td><td>CD19<\/td><td>B-sejtes limf\u00f3ma<\/td><td>NMPA<\/td><\/tr><tr><td>Zever-cel<\/td><td>\u2014<\/td><td>CD19\/BCMA<\/td><td>Haematolog.<\/td><td>NMPA<\/td><\/tr><tr><td>Carvykti<\/td><td>Ciltacabtagene autoleucel<\/td><td>BCMA<\/td><td>Mult. myeloma<\/td><td>NMPA 2024<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Indien_CDSCO\"><\/span>India (CDSCO)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>NexCAR19<\/strong> (Actalycabtagene autoleucel) 2023 okt\u00f3ber\u00e9ben kapta meg az els\u0151 Indi\u00e1ban kifejlesztett CAR-T ter\u00e1pia enged\u00e9ly\u00e9t. Az IIT Bombayben az ImmunoACT \u00e1ltal kifejlesztett ter\u00e1pia \u00e1ra k\u00f6r\u00fclbel\u00fcl 50 000 USD - a hasonl\u00f3 nyugati term\u00e9kek mintegy tizede. <a href=\"https:\/\/www.dasgelbeblatt.de\/welt\/immunzelltherapie-heilt-ueberraschend-krebs-bei-einem-jugendlichen-zr-94168662.html\" target=\"_blank\" rel=\"noreferrer noopener\">A s\u00e1rga lev\u00e9l<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Jelz\u00e9s<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Relapsz\u00e1lt\/refrakter B-sejtes non-Hodgkin limf\u00f3ma \u00e9s B-sejtes ALL<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Kezel\u0151k\u00f6zpont:<\/strong> Tata Memorial K\u00f3rh\u00e1z, Mumbai <br><strong>Gy\u00e1rt\u00f3:<\/strong> <a href=\"https:\/\/www.immunoact.com\" target=\"_blank\" rel=\"noopener\">ImmunoACT<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"TCR-T-ZELLTHERAPIEN_zugelassen\"><\/span>TCR-T CELL TER\u00c1PI\u00c1K (enged\u00e9lyezett)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Afamitresgene_Autoleucel_Tecelra%C2%AE_%E2%80%93_Adaptimmune_August_2024\"><\/span>Afamitresgene Autoleucel (Tecelra\u00ae) - <em>Adaptimmun<\/em> <em>(2024. augusztus)<\/em><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">2024. augusztus 2-\u00e1n az FDA enged\u00e9lyezte az Afamitresgene autoleucel (Afami-cel, Tecelra) mint a r\u00e1k kezel\u00e9s\u00e9re szolg\u00e1l\u00f3 els\u0151 TCR T-sejtes ter\u00e1pi\u00e1t, \u00e9s k\u00fcl\u00f6n\u00f6sen az els\u0151 genetikailag m\u00f3dos\u00edtott T-sejtes k\u00e9sz\u00edtm\u00e9nyt szil\u00e1rd daganat kezel\u00e9s\u00e9re. <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12283372\/\" target=\"_blank\" rel=\"noreferrer noopener\">PubMed Central<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>C\u00e9lzott antig\u00e9n:<\/strong> MAGE-A4 (intracellul\u00e1ris r\u00e1kos here antig\u00e9n), HLA-A*02:01 \u00e1ltal prezent\u00e1lva.<br><strong>Enged\u00e9lyezve:<\/strong> FDA augusztus 2024<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Jelz\u00e9s<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Feln\u0151ttek nem oper\u00e1lhat\u00f3 vagy \u00e1tt\u00e9tes r\u00e1kos megbeteged\u00e9ssel <strong>Szinovi\u00e1lis szark\u00f3ma<\/strong> (l\u00e1gyr\u00e9szszark\u00f3ma), kemoter\u00e1pi\u00e1val el\u0151kezelt, MAGE-A4-pozit\u00edv \u00e9s HLA-A*02:01-pozit\u00edv<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">A SPEARHEAD-1 f\u00e1zis\u00fa, 2. f\u00e1zis\u00fa, kulcsfontoss\u00e1g\u00fa vizsg\u00e1latban a szinovi\u00e1lis szark\u00f3m\u00e1s betegek daganatai \u00e1tlagosan 11,6 h\u00f3napig reag\u00e1ltak a kezel\u00e9sre. N\u00e9h\u00e1ny betegn\u00e9l t\u00f6bb \u00e9vig nem lehetett tumort kimutatni. <a href=\"https:\/\/www.clinicaltrialvanguard.com\/news\/t-knife-files-for-phase-1-trial-of-prame-t-cell-therapy\/\" target=\"_blank\" rel=\"noreferrer noopener\">Clinicaltrialvanguard<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>A legfontosabb tanulm\u00e1ny<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>SPEARHEAD-1 (2. f\u00e1zis): <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04044858\" target=\"_blank\" rel=\"noopener\">NCT04044858<\/a> | <a href=\"https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(24)00319-2\/fulltext\" target=\"_blank\" rel=\"noopener\">Lancet \u00e1prilis 2024<\/a><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Kezel\u0151k\u00f6zpont (Pioneer):<\/strong> Memorial Sloan Kettering R\u00e1kk\u00f6zpont, New York - <a href=\"https:\/\/www.mskcc.org\/news\/immunotherapy-clinical-trial-shows-promise-for-treating-rare-sarcomas\" target=\"_blank\" rel=\"noopener\">MSK Tecelra Info<\/a><br><strong>FDA term\u00e9koldal:<\/strong> <a href=\"https:\/\/www.fda.gov\/vaccines-blood-biologics\/tecelra\" target=\"_blank\" rel=\"noopener\">FDA Tecelra<\/a> <br><strong>NCI cikk:<\/strong> <a href=\"https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2024\/fda-tecelra-synovial-sarcoma-mage-a4\" target=\"_blank\" rel=\"noopener\">cancer.gov TCR ter\u00e1pia<\/a><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Tebentafusp-tebn_Kimmtrak%C2%AE_%E2%80%93_Immunocore_Januar_2022\"><\/span>Tebentafusp-tebn (Kimmtrak\u00ae) - <em>Immunocore<\/em> <em>(2022. janu\u00e1r)<\/em><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Nem klasszikus sejtterm\u00e9k (nem infund\u00e1lt T-sejt term\u00e9k), hanem bispecifikus TCR f\u00fazi\u00f3s feh\u00e9rje, de mechanisztikailag a TCR-alap\u00fa immunter\u00e1pia kateg\u00f3ri\u00e1j\u00e1ba tartozik, \u00e9s gyakran a PRAME-TCER\u00ae technol\u00f3gia el\u0151fut\u00e1rak\u00e9nt t\u00e1rgyalj\u00e1k.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Mechanizmus:<\/strong> Egyik oldalon a daganatsejteken l\u00e9v\u0151 gp100 peptid+HLA-A*02:01, a m\u00e1sik oldalon a T-sejteken l\u00e9v\u0151 CD3 peptidhez k\u00f6t\u0151dik (ImmTAC technol\u00f3gia).<br><strong>Enged\u00e9lyezve:<\/strong> FDA 2022. janu\u00e1r \/ EMA 2022. febru\u00e1r<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Jelz\u00e9s:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>HLA-A*02:01-pozit\u00edv feln\u0151ttek nem oper\u00e1lhat\u00f3 vagy \u00e1tt\u00e9tes daganatos betegs\u00e9gben <strong>uve\u00e1lis melanoma<\/strong> (szemmelanoma) - 1. vonal<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>K\u00fcl\u00f6nlegess\u00e9g:<\/strong> A valaha enged\u00e9lyezett els\u0151 gy\u00f3gyszer a szembeteg melanoma kezel\u00e9s\u00e9re<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A 3. f\u00e1zis\u00fa IMCgp100-202 vizsg\u00e1latban a tebentafuszp szignifik\u00e1ns t\u00fal\u00e9l\u00e9si el\u0151nyt mutatott az orvos \u00e1ltal v\u00e1lasztott (pembrolizumab, ipilimumab vagy dakarbazin) ter\u00e1pi\u00e1val szemben: medi\u00e1n OS 21,7 vs. 16,0 h\u00f3nap (HR 0,51; p&lt;0,0001). Az 1 \u00e9ves OS ar\u00e1ny 73 volt % vs. 59 %. <a href=\"https:\/\/www.kitz-heidelberg.de\/das-kitz\/kitz-programme\/\" target=\"_blank\" rel=\"noreferrer noopener\">Kitz-heidelberg<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>A legfontosabb tanulm\u00e1ny<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>IMCgp100-202 (3. f\u00e1zis): <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT03070392\" target=\"_blank\" rel=\"noopener\">NCT03070392<\/a> | <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2103485\" target=\"_blank\" rel=\"noopener\">NEJM 2021<\/a> | <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2304753\" target=\"_blank\" rel=\"noopener\">3 \u00e9ves friss\u00edt\u00e9s NEJM 2023<\/a><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>FDA oldal:<\/strong> <a href=\"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-disco-burst-edition-fda-approves-tebentafusp-tebn-unresectable-or-metastatic-uveal-melanoma\" target=\"_blank\" rel=\"noopener\">fda.gov Kimmtrak<\/a> <br><strong>Gy\u00e1rt\u00f3:<\/strong> <a href=\"https:\/\/www.immunocore.com\/pipeline\/kimmtrak\" target=\"_blank\" rel=\"noopener\">immunocore.com\/kimmtrak<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"TIL-THERAPIE_zugelassen\"><\/span>TIL-TER\u00c1PIA (enged\u00e9lyezett)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Lifileucel_Amtagvi%C2%AE_%E2%80%93_Iovance_Biotherapeutics_Februar_2024\"><\/span>Lifileucel (Amtagvi\u00ae) - <em>Iovance Biotherapeutics<\/em> <em>(2024. febru\u00e1r)<\/em><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">A Lifileucel-t 2024. febru\u00e1r 16-\u00e1n hagyt\u00e1k j\u00f3v\u00e1, mint az els\u0151 T-sejtes ter\u00e1pi\u00e1t szil\u00e1rd daganat kezel\u00e9s\u00e9re, \u00e9s egyben a t\u00f6rt\u00e9nelem els\u0151 TIL-ter\u00e1pi\u00e1j\u00e1t. <a href=\"https:\/\/investors.immatics.com\/news-releases\/news-release-details\/immatics-initiates-phase-12-clinical-trial-evaluate-prame-tcr\/\" target=\"_blank\" rel=\"noreferrer noopener\">Immatics N.V.<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Mechanizmus:<\/strong> A daganatot m\u0171t\u00e9tileg elt\u00e1vol\u00edtj\u00e1k, a tumorba besziv\u00e1rg\u00f3 limfocit\u00e1kat (TIL) izol\u00e1lj\u00e1k, t\u00f6megesen szapor\u00edtj\u00e1k \u00e9s a limfodepleti\u00f3t k\u00f6vet\u0151en \u00fajra beadj\u00e1k. Nincs genetikai m\u00f3dos\u00edt\u00e1s - a TIL term\u00e9szetes tumorfelismer\u00e9s\u00e9t haszn\u00e1lj\u00e1k.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Jelz\u00e9s<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Feln\u0151ttek nem oper\u00e1lhat\u00f3 vagy \u00e1tt\u00e9tes r\u00e1kos megbeteged\u00e9ssel <strong>Melanoma<\/strong> (cutan melanoma) el\u0151zetes anti-PD-1 ter\u00e1pia \u00e9s BRAF\/MEK-g\u00e1tl\u00f3 (ha BRAF-mut\u00e1lt) ut\u00e1n.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">A 2. f\u00e1zis\u00fa C-144-01 vizsg\u00e1lat 5 \u00e9ves k\u00f6vet\u00e9se sor\u00e1n a Lifileucel 31,4 % objekt\u00edv v\u00e1laszad\u00e1si ar\u00e1nyt \u00e9s 36,5 h\u00f3napos medi\u00e1n v\u00e1laszad\u00e1si id\u0151tartamot mutatott ki - t\u00f6bb mint 30 %-reag\u00e1l\u00f3 eset\u00e9ben tart\u00f3s, hossz\u00fa t\u00e1v\u00fa v\u00e1laszad\u00e1ssal. <a href=\"https:\/\/dailyreporter.esmo.org\/esmo-immuno-oncology-congress-2025\/news\/next-generation-prame-directed-tcr-t-cell-therapy-shows-early-activity-in-solid-tumours\" target=\"_blank\" rel=\"noreferrer noopener\">Esmo<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>A legfontosabb tanulm\u00e1ny<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>C-144-01 (2. f\u00e1zis, NCT02360579): <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT02360579\" target=\"_blank\" rel=\"noopener\">ClinicalTrials<\/a> | <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40699950\/\" target=\"_blank\" rel=\"noopener\">FDA j\u00f3v\u00e1hagy\u00e1s \u00f6sszefoglal\u00f3ja PubMed<\/a><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Kezel\u0151k\u00f6zpontok (USA kiv\u00e1laszt\u00e1s):<\/strong> Johns Hopkins, UCLA, MD Anderson, UCSF, Memorial Sloan Kettering, Mayo Klinika<br><strong>NCI cikk:<\/strong> <a href=\"https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2024\/fda-amtagvi-til-therapy-melanoma\" target=\"_blank\" rel=\"noopener\">cancer.gov TIL ter\u00e1pia<\/a><br><strong>Gy\u00e1rt\u00f3:<\/strong> <a href=\"https:\/\/www.iovance.com\" target=\"_blank\" rel=\"noopener\">iovance.com<\/a><br><strong>FDA term\u00e9koldal:<\/strong> <a href=\"https:\/\/www.fda.gov\/vaccines-blood-biologics\/amtagvi\" target=\"_blank\" rel=\"noopener\">FDA Amtagvi<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Ubersicht_aller_Immunzelltherapien_weltweit\"><\/span>A vil\u00e1gszerte alkalmazott immunsejtes ter\u00e1pi\u00e1k \u00e1ttekint\u00e9se<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Term\u00e9k<\/th><th>Akt\u00edv \u00f6sszetev\u0151<\/th><th>T\u00edpus<\/th><th>C\u00e9l<\/th><th>Jelz\u00e9s<\/th><th>Enged\u00e9lyez\u00e9s<\/th><th>\u00c9v<\/th><\/tr><\/thead><tbody><tr><td><strong>Kymriah<\/strong><\/td><td>Tisagenlecleucel<\/td><td>CAR-T<\/td><td>CD19<\/td><td>B-ALL gyermekgy\u00f3gy\u00e1szat, LBCL, FL<\/td><td>FDA, EMA<\/td><td>2017<\/td><\/tr><tr><td><strong>Yescarta<\/strong><\/td><td>Axicabtagene-cel<\/td><td>CAR-T<\/td><td>CD19<\/td><td>DLBCL, PMBCL, FL, tFL<\/td><td>FDA, EMA<\/td><td>2017<\/td><\/tr><tr><td><strong>Tecartus<\/strong><\/td><td>Brexucabtagene-cel<\/td><td>CAR-T<\/td><td>CD19<\/td><td>MCL, feln\u0151tt B-ALL<\/td><td>FDA, EMA<\/td><td>2020<\/td><\/tr><tr><td><strong>Breyanzi<\/strong><\/td><td>Lisocabtagene-cel<\/td><td>CAR-T<\/td><td>CD19<\/td><td>LBCL, CLL\/SLL, FL<\/td><td>FDA, EMA<\/td><td>2021<\/td><\/tr><tr><td><strong>Abecma<\/strong><\/td><td>Idecabtagene-cel<\/td><td>CAR-T<\/td><td>BCMA<\/td><td>Mult. Myeloma \u22654 vonal<\/td><td>FDA, EMA<\/td><td>2021<\/td><\/tr><tr><td><strong>Carvykti<\/strong><\/td><td>Ciltacabtagene-cel<\/td><td>CAR-T<\/td><td>BCMA<\/td><td>Mult. Myeloma \u22651 vonal<\/td><td>FDA, EMA, NMPA<\/td><td>2022<\/td><\/tr><tr><td><strong>Kimmtrak<\/strong><\/td><td>Tebentafusp-tebn<\/td><td>TCR-bispecifikus<\/td><td>gp100+HLA<\/td><td>Uve\u00e1lis melanoma<\/td><td>FDA, EMA<\/td><td>2022<\/td><\/tr><tr><td><strong>NexCAR19<\/strong><\/td><td>Actalycabtagene-cel<\/td><td>CAR-T<\/td><td>CD19<\/td><td>B-ALL, NHL<\/td><td>CDSCO (India)<\/td><td>2023<\/td><\/tr><tr><td><strong>Amtagvi<\/strong><\/td><td>Lifileucel<\/td><td>TIL<\/td><td>Poliklon\u00e1lis<\/td><td>Melanoma (szil\u00e1rd daganat)<\/td><td>FDA<\/td><td>2024<\/td><\/tr><tr><td><strong>Tecelra<\/strong><\/td><td>Afamitresgene-cel<\/td><td>TCR-T<\/td><td>MAGE-A4+HLA<\/td><td>Szinovi\u00e1lis szark\u00f3ma<\/td><td>FDA<\/td><td>2024<\/td><\/tr><tr><td><strong>Aucatzyl<\/strong><\/td><td>Obecabtagene-cel<\/td><td>CAR-T<\/td><td>CD19<\/td><td>Feln\u0151tt B-ALL<\/td><td>FDA<\/td><td>2024<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Nebenwirkungen_%E2%80%93_Was_alle_Therapien_verbindet\"><\/span>Mell\u00e9khat\u00e1sok - mi a k\u00f6z\u00f6s a ter\u00e1pi\u00e1kban?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">A legfontosabb k\u00f6z\u00f6s kock\u00e1zatok:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Citokin vihar (CRS)<\/strong><br>Gyakran fordul el\u0151 CAR-T \u00e9s TCR-T eset\u00e9n; ritk\u00e1n TIL eset\u00e9n.<br>Kezel\u00e9s tocilizumabbal.<br>2024 \u00f3ta minden CAR-T c\u00edmk\u00e9n: dobozos figyelmeztet\u00e9s a m\u00e1sodlagos T-sejtes rosszindulat\u00fa daganatokra (nagyon ritka, ~3,6 % az \u00e9vek sor\u00e1n).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>ICANS (neurotoxicit\u00e1s)<\/strong><br>Immunsejt-asszoci\u00e1lt neurotoxicit\u00e1s szindr\u00f3ma; CAR-T eset\u00e9ben ismert, TIL eset\u00e9ben ritk\u00e1bban fordul el\u0151.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Cytopenias<\/strong><br>A sz\u00fcks\u00e9ges limfodepletio (inf\u00fazi\u00f3 el\u0151tti kemoter\u00e1pia) mindig r\u00f6vid t\u00e1v\u00fa v\u00e9rk\u00e9p-v\u00e1ltoz\u00e1st eredm\u00e9nyez.<\/p>\n\n\n\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wo_werden_diese_Therapien_in_Deutschland_angeboten\"><\/span>Hol k\u00edn\u00e1lj\u00e1k ezeket a ter\u00e1pi\u00e1kat N\u00e9metorsz\u00e1gban?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Minden FDA\/EMA \u00e1ltal j\u00f3v\u00e1hagyott CAR-T term\u00e9ket a k\u00f6vetkez\u0151 helyeken \u00e1ll\u00edtanak el\u0151 <strong>specializ\u00e1lt transzplant\u00e1ci\u00f3s k\u00f6zpontok<\/strong> a gy\u00e1rt\u00f3k \u00e1ltal tan\u00fas\u00edtott \u00e9s a DKMS\/EBMT \u00e1ltal akkredit\u00e1lt:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Egyetemi Orvosi K\u00f6zpont Hamburg-Eppendorf (UKE):<\/strong> <a href=\"https:\/\/www.uke.de\" target=\"_blank\" rel=\"noopener\">uke.de<\/a><\/li>\n\n\n\n<li><strong>Charit\u00e9 - Universit\u00e4tsmedizin Berlin:<\/strong> <a href=\"https:\/\/www.charite.de\" target=\"_blank\" rel=\"noopener\">charite.de<\/a><\/li>\n\n\n\n<li><strong>LMU Klinikai K\u00f6zpont M\u00fcnchen:<\/strong> <a href=\"https:\/\/www.lmu-klinikum.de\" target=\"_blank\" rel=\"noopener\">lmu-klinikum.de<\/a><\/li>\n\n\n\n<li><strong>Heidelbergi Egyetemi K\u00f3rh\u00e1z \/ KiTZ:<\/strong> <a href=\"https:\/\/www.kitz-heidelberg.de\" target=\"_blank\" rel=\"noopener\">kitz-heidelberg.de<\/a> <em>(szint\u00e9n: PRAME kutat\u00e1s)<\/em><\/li>\n\n\n\n<li><strong>Frankfurti Egyetemi K\u00f3rh\u00e1z:<\/strong> <a href=\"https:\/\/www.uniklinik-frankfurt.de\" target=\"_blank\" rel=\"noopener\">uniklinik-frankfurt.de<\/a><\/li>\n\n\n\n<li><strong>Freiburgi Egyetemi Orvosi K\u00f6zpont:<\/strong> <a href=\"https:\/\/www.uniklinik-freiburg.de\" target=\"_blank\" rel=\"noopener\">uniklinik-freiburg.de<\/a><\/li>\n\n\n\n<li><strong>D\u00fcsseldorfi Egyetemi K\u00f3rh\u00e1z \/ Essen:<\/strong> az MCL\/DLBCL-CAR-T-re specializ\u00e1l\u00f3dott<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>A tan\u00fas\u00edtott CAR-T k\u00f6zpontok teljes list\u00e1ja:<\/strong> <a href=\"https:\/\/www.ebmt.org\/registry\/center-search\" target=\"_blank\" rel=\"noopener\">EBMT K\u00f6zpont keres\u00e9s<\/a><\/p>\n\n\n\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Ausblick_Was_kommt_als_nachstes\"><\/span>Kil\u00e1t\u00e1sok: Mi a k\u00f6vetkez\u0151 l\u00e9p\u00e9s?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">A j\u00f3v\u00e1hagyott immunsejtter\u00e1pi\u00e1k k\u00f6vetkez\u0151 hull\u00e1ma v\u00e1rhat\u00f3an 2026-2028 k\u00f6z\u00f6tt \u00e9rkezik:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>IMA203 \/ Anzu-cel (PRAME-TCR):<\/strong> F\u00e1zis 3 SUPRAME vizsg\u00e1lat folyamatban - <em>Lehets\u00e9ges enged\u00e9ly a melanoma kezel\u00e9s\u00e9re 2027\/2028<\/em><\/li>\n\n\n\n<li><strong>Lifileucel + pembrolizumab (3. f\u00e1zis):<\/strong> Els\u0151 vonalbeli vizsg\u00e1lat NCT05727904 - <em>Lehets\u00e9ges els\u0151 vonalbeli j\u00f3v\u00e1hagy\u00e1s melan\u00f3m\u00e1ra<\/em><\/li>\n\n\n\n<li><strong>Brenetafusp (PRISM-MEL-301):<\/strong> 3. f\u00e1zis\u00fa vizsg\u00e1lat PRAME\u00d7CD3-Bispecifikus - <em>Lehets\u00e9ges enged\u00e9lyez\u00e9s 2027<\/em><\/li>\n\n\n\n<li><strong>CAR-T autoimmun betegs\u00e9gek (SLE, MS) kezel\u00e9s\u00e9re:<\/strong> F\u00e1zis 2 vizsg\u00e1latok folyamatban; potenci\u00e1lisan az els\u0151 nem onkol\u00f3giai CAR-T term\u00e9k<\/li>\n\n\n\n<li><strong>KiTZ Heidelberg gyermekgy\u00f3gy\u00e1szati PRAME vizsg\u00e1lat:<\/strong> 2026-ra tervezik - a vil\u00e1g els\u0151 gyermekeknek sz\u00f3l\u00f3 tanulm\u00e1nya<\/li>\n<\/ul>\n\n\n\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"GKV-Erstattung_von_Immunzelltherapien_in_Deutschland\"><\/span>Az immunsejtter\u00e1pi\u00e1k SHI-visszat\u00e9r\u00edt\u00e9se N\u00e9metorsz\u00e1gban<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p class=\"wp-block-paragraph\">\u00c1llapot 02.2026<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A helyzet \u00f6sszetett, \u00e9s a ter\u00e1pia t\u00edpus\u00e1t\u00f3l, a term\u00e9kt\u0151l \u00e9s az eg\u00e9szs\u00e9gbiztos\u00edt\u00f3t\u00f3l f\u00fcgg\u0151en nagym\u00e9rt\u00e9kben v\u00e1ltozik. Nincs \u00e1tal\u00e1nyd\u00edjas, automatikus visszat\u00e9r\u00edt\u00e9s, mint a hagyom\u00e1nyos gy\u00f3gyszerek eset\u00e9ben. Ehelyett egy t\u00f6bbl\u00e9pcs\u0151s rendszer van \u00e9rv\u00e9nyben, jelent\u0151s b\u00fcrokr\u00e1ci\u00e1val, amelyet az orvosok \u00e9s a klinik\u00e1k ny\u00edltan kritiz\u00e1lnak, mint diszfunkcion\u00e1lis rendszert.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"CAR-T-Zelltherapien\"><\/span>CAR-T sejtter\u00e1pi\u00e1k<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">\u00c1ltal\u00e1ban visszat\u00e9r\u00edtend\u0151, de bonyolult<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"AMNOG_NUB-Verfahren\"><\/span>AMNOG \u00e9s NUB elj\u00e1r\u00e1s<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">A CAR-T k\u00e9sz\u00edtm\u00e9nyek <strong>Fejlett ter\u00e1pi\u00e1s gy\u00f3gyszerk\u00e9sz\u00edtm\u00e9nyek (ATMP)<\/strong> \u00e9s a n\u00e9met <strong>AMNOG elj\u00e1r\u00e1s<\/strong> (A gy\u00f3gyszerpiac \u00fajj\u00e1szervez\u00e9s\u00e9r\u0151l sz\u00f3l\u00f3 t\u00f6rv\u00e9ny). Ez el\u0151\u00edrja a k\u00f6vetkez\u0151ket<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Fruhe_Nutzenbewertung_durch_den_G-BA\"><\/span>A G-BA \u00e1ltal v\u00e9gzett korai haszon\u00e9rt\u00e9kel\u00e9s<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">2011. janu\u00e1r 1-je \u00f3ta a G-BA t\u00f6rv\u00e9nyben el\u0151\u00edrt feladata, hogy a forgalomba hozatal ut\u00e1n azonnal elv\u00e9gezze az \u00faj hat\u00f3anyag\u00fa, \u00fajonnan enged\u00e9lyezett gy\u00f3gyszerek el\u0151nyeinek \u00e9rt\u00e9kel\u00e9s\u00e9t.<br>Azt vizsg\u00e1lj\u00e1k, hogy az \u00faj gy\u00f3gyszer jobb-e, mint a kor\u00e1bbi standard ter\u00e1pia - az \u00fan. <strong>megfelel\u0151 \u00f6sszehasonl\u00edt\u00f3 ter\u00e1pia<\/strong> - el\u0151nyt k\u00edn\u00e1l.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Jogalap:<\/strong> <a href=\"https:\/\/www.gesetze-im-internet.de\/sgb_5\/__35a.html\" target=\"_blank\" rel=\"noopener\">\u00a7 SGB V 35a. szakasz - A gy\u00f3gyszerek el\u0151nyeinek \u00e9rt\u00e9kel\u00e9se (jogi megfogalmaz\u00e1s)<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Az elj\u00e1r\u00e1s le\u00edr\u00e1sa G-BA:<\/strong> <a href=\"https:\/\/www.g-ba.de\/themen\/arzneimittel\/arzneimittel-richtlinie-anlagen\/nutzenbewertung-35a\/\" target=\"_blank\" rel=\"noopener\">g-ba.de - AMNOG ell\u00e1t\u00e1s \u00e9rt\u00e9kel\u00e9se az SGB V 35a \u00a7-a szerint<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A GKV-Spitzenverband \u00e9s a gy\u00f3gyszergy\u00e1rt\u00f3 k\u00f6z\u00f6tti \u00e1rt\u00e1rgyal\u00e1sok kiindul\u00f3pontja a haszon\u00e9rt\u00e9kel\u00e9s eredm\u00e9nye.<br>A t\u00f6bbletjuttat\u00e1s \u00e9rt\u00e9kel\u00e9s\u00e9nek lehets\u00e9ges kateg\u00f3ri\u00e1it a n\u00e9met gy\u00f3gyszer-el\u0151ny\u00e9rt\u00e9kel\u00e9si rendelet \u00e9s a G-BA elj\u00e1r\u00e1si szab\u00e1lyzat\u00e1nak 5. fejezete hat\u00e1rozza meg.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A kieg\u00e9sz\u00edt\u0151 juttat\u00e1sok n\u00e9gy kateg\u00f3ri\u00e1ja a k\u00f6vetkez\u0151:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Jelent\u0151s<\/strong> Tov\u00e1bbi el\u0151ny\u00f6k<\/li>\n\n\n\n<li><strong>Jelent\u0151s<\/strong> Tov\u00e1bbi el\u0151ny\u00f6k<\/li>\n\n\n\n<li><strong>Als\u00f3<\/strong> Tov\u00e1bbi el\u0151ny\u00f6k<\/li>\n\n\n\n<li><strong>Nincs<\/strong> Bizony\u00edtott tov\u00e1bbi el\u0151ny\u00f6k<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>A n\u00e9gy kateg\u00f3ria az eredeti megfogalmaz\u00e1sban:<\/strong> <a href=\"https:\/\/www.g-ba.de\/themen\/arzneimittel\/arzneimittel-richtlinie-anlagen\/nutzenbewertung-35a\/zusatznutzen\/\" target=\"_blank\" rel=\"noopener\">g-ba.de - A hozz\u00e1adott \u00e9rt\u00e9k kateg\u00f3ri\u00e1i<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>A kateg\u00f3ri\u00e1k jogalapja:<\/strong> <a href=\"https:\/\/www.gesetze-im-internet.de\/am-nutzenv\/BJNR232400010.html\" target=\"_blank\" rel=\"noopener\">AM-NutzenV 5. \u00a7 (7) bekezd\u00e9s - Gy\u00f3gyszerk\u00f6lts\u00e9g-elb\u00edr\u00e1l\u00e1si rendelet (jogi megfogalmaz\u00e1s)<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Konkr\u00e9t p\u00e9lda: G-BA elj\u00e1r\u00e1s a Yescarta (CAR-T) eset\u00e9ben:<\/strong> <a href=\"https:\/\/www.g-ba.de\/bewertungsverfahren\/nutzenbewertung\/406\/\" target=\"_blank\" rel=\"noopener\">g-ba.de - Hasznoss\u00e1gi vizsg\u00e1lati elj\u00e1r\u00e1s Axicabtagene-Ciloleucel<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Minden folyamatban l\u00e9v\u0151 \u00e9s befejezett G-BA \u00e9rt\u00e9kel\u00e9si elj\u00e1r\u00e1s:<\/strong> <a href=\"https:\/\/www.g-ba.de\/bewertungsverfahren\/nutzenbewertung\/\" target=\"_blank\" rel=\"noopener\">g-ba.de - Az \u00e9rt\u00e9kel\u00e9si elj\u00e1r\u00e1s \u00e1ttekint\u00e9se<\/a><\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Preisverhandlung_nach_%C2%A7_130b_SGB_V\"><\/span>\u00c1rat\u00e1rgyal\u00e1s az SGB V 130b \u00a7-a szerint<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">A G-BA \u00faj gy\u00f3gyszerk\u00e9sz\u00edtm\u00e9ny t\u00f6bblethaszn\u00e1r\u00f3l sz\u00f3l\u00f3 d\u00f6nt\u00e9se alapj\u00e1n a GKV-Spitzenverband \u00e9s a gy\u00f3gyszergy\u00e1rt\u00f3 c\u00e9g \u00e1ltal\u00e1ban hat h\u00f3napon bel\u00fcl n\u00e9gy t\u00e1rgyal\u00e1si \u00fcl\u00e9sen t\u00e1rgyal az \u00fagynevezett visszat\u00e9r\u00edt\u00e9si \u00f6sszegr\u0151l. Ez a forgalomba hozatalt k\u00f6vet\u0151 hetedik h\u00f3napt\u00f3l \u00e9rv\u00e9nyes, mint \u00faj orsz\u00e1gos kiad\u00e1si \u00e1r - a t\u00f6rv\u00e9nyes eg\u00e9szs\u00e9gbiztos\u00edt\u00e1ssal rendelkez\u0151k, a mag\u00e1nbiztos\u00edt\u00e1ssal rendelkez\u0151k \u00e9s az \u00f6nfizet\u0151k sz\u00e1m\u00e1ra egyar\u00e1nt.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Jogalap:<\/strong> <a href=\"https:\/\/www.gesetze-im-internet.de\/sgb_5\/__130b.html\" target=\"_blank\" rel=\"noopener\">\u00a7 SGB V 130b. szakasz - Meg\u00e1llapod\u00e1sok a visszat\u00e9r\u00edt\u00e9si \u00f6sszegekr\u0151l (a t\u00f6rv\u00e9ny sz\u00f6vege)<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Az elj\u00e1r\u00e1s le\u00edr\u00e1sa GKV-Spitzenverband:<\/strong> <a href=\"https:\/\/www.gkv-spitzenverband.de\/krankenversicherung\/arzneimittel\/verhandlungen_nach_amnog\/rabatt_verhandlungen_nach_amnog.jsp\" target=\"_blank\" rel=\"noopener\">gkv-spitzenverband.de - AMNOG t\u00e1rgyal\u00e1sok az SGB V 130b \u00a7 szerint<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Az \u00f6sszes t\u00e1rgyal\u00e1sos visszat\u00e9r\u00edt\u00e9si \u00f6sszegek \u00e1ttekint\u00e9se (bele\u00e9rtve a CAR-T term\u00e9keket is):<\/strong> <a href=\"https:\/\/www.gkv-spitzenverband.de\/krankenversicherung\/arzneimittel\/verhandlungen_nach_amnog\/ebv_130b\/ebv_nach_130b.jsp\" target=\"_blank\" rel=\"noopener\">gkv-spitzenverband.de - Visszat\u00e9r\u00edt\u00e9si \u00f6sszegekr\u0151l sz\u00f3l\u00f3 meg\u00e1llapod\u00e1sok<\/a><\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"NUB-Verfahren_fur_Krankenhauser\"><\/span>NUB-elj\u00e1r\u00e1s k\u00f3rh\u00e1zak sz\u00e1m\u00e1ra<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Mivel a CAR-T ter\u00e1pi\u00e1kat fekv\u0151beteg-alapon adj\u00e1k, a klinik\u00e1k is a <strong>NUB elj\u00e1r\u00e1s<\/strong> (\u00daj vizsg\u00e1lati \u00e9s kezel\u00e9si m\u00f3dszerek a KHEntgG 6. \u00a7 (2) bekezd\u00e9se szerint).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A NUB-elj\u00e1r\u00e1s az \u00fagynevezett \u201einnov\u00e1ci\u00f3s szakad\u00e9kot\u201c z\u00e1rja le, vagyis azt az \u00e1ltal\u00e1ban h\u00e1rom\u00e9ves id\u0151szakot, am\u00edg egy \u00faj ter\u00e1pia teljes m\u00e9rt\u00e9kben be\u00e9p\u00fcl a G-DRG \u00e1tal\u00e1nyrendszerbe.<br>Ebben az id\u0151szakban a k\u00f3rh\u00e1zak k\u00f3rh\u00e1zspecifikus NUB-d\u00edjakr\u00f3l t\u00e1rgyalhatnak az eg\u00e9szs\u00e9gbiztos\u00edt\u00e1si p\u00e9nzt\u00e1rakkal, felt\u00e9ve, hogy a K\u00f3rh\u00e1zi Javadalmaz\u00e1si Rendszer Int\u00e9zet (InEK) fel\u00fclvizsg\u00e1lat ut\u00e1n 1-es st\u00e1tuszt ad.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A k\u00f3rh\u00e1zaknak minden \u00e9v okt\u00f3ber 31-ig kell beny\u00fajtaniuk a NUB-k\u00e9relmeket az InEK-hez. Az InEK a k\u00f6vetkez\u0151 \u00e9v janu\u00e1r v\u00e9g\u00e9ig k\u00f6zz\u00e9teszi a fel\u00fclvizsg\u00e1lat eredm\u00e9ny\u00e9t.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Az ATMP-kre (fejlett ter\u00e1pi\u00e1s gy\u00f3gyszerk\u00e9sz\u00edtm\u00e9nyek) - ide tartozik minden CAR-T \u00e9s TCR-T term\u00e9k - minden \u00e9v \u00e1prilis 30-ig meghosszabb\u00edtott k\u00e9relmez\u00e9si hat\u00e1rid\u0151 vonatkozik, kiv\u00e9ve, ha a k\u00e9relmet okt\u00f3ber 31-ig m\u00e1r beny\u00fajtott\u00e1k.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>NUB elj\u00e1r\u00e1s hivatalos (InEK):<\/strong> <a href=\"https:\/\/www.g-drg.de\/neue-untersuchungs-und-behandlungsmethoden-nub\/drg\" target=\"_blank\" rel=\"noopener\">g-drg.de - NUB-elj\u00e1r\u00e1s az ATMP-kre vonatkoz\u00f3an<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>NUB-elj\u00e1r\u00e1s (GKV-Spitzenverband):<\/strong> <a href=\"https:\/\/www.gkv-spitzenverband.de\/krankenversicherung\/krankenhaeuser\/drg_system\/neue_untersuchungs_und_behandlungsmethoden_nub\/neue_untersuchungs_und_behandlungsmethoden_nub.jsp\" target=\"_blank\" rel=\"noopener\">gkv-spitzenverband.de - NUB a k\u00f3rh\u00e1zakban<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>R\u00e9szletes folyamatmagyar\u00e1zat az ATMP k\u00fcl\u00f6nleges szab\u00e1lyoz\u00e1ssal:<\/strong> <a href=\"https:\/\/reimbursement.institute\/nub-antrag\/\" target=\"_blank\" rel=\"noopener\">visszat\u00e9r\u00edt\u00e9s.int\u00e9zet - NUB megkeres\u00e9si elj\u00e1r\u00e1s<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>AOK \u00e1ttekint\u00e9s NUB 2025 (a jelenlegi \u00e1llapotra vonatkoz\u00f3 adatokkal):<\/strong> <a href=\"https:\/\/www.aok.de\/gp\/krankenhaus\/verguetung-drg\/nub\" target=\"_blank\" rel=\"noopener\">aok.de\/gp - NUB a szomatik\u00e1ban<\/a><\/p>\n\n\n\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Die_Realitat_Einzelfallantrage_und_Burokratie\"><\/span>A val\u00f3s\u00e1g: egyedi k\u00e9relmek \u00e9s b\u00fcrokr\u00e1cia<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">A kialkudott t\u00e9r\u00edt\u00e9si \u00f6sszegek ellen\u00e9re a klinik\u00e1k \u00e9s a betegek sz\u00e1m\u00e1ra a gyakorlat l\u00e9nyegesen bonyolultabb, mint azt a hivatalos szab\u00e1lyoz\u00e1s sugalln\u00e1.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Eddig a k\u00f6zpontoknak \u00e1ltal\u00e1ban egy\u00e9ni k\u00e9relmet kellett beny\u00fajtaniuk a t\u00f6rv\u00e9nyes eg\u00e9szs\u00e9gbiztos\u00edt\u00e1s \u00e1ltal fedezett k\u00f6lts\u00e9gek fedez\u00e9s\u00e9re.<br>Nincs egys\u00e9ges, automatikus k\u00f6lts\u00e9gfedezet a k\u00f6telez\u0151 eg\u00e9szs\u00e9gbiztos\u00edt\u00e1ssal rendelkez\u0151k sz\u00e1m\u00e1ra.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forr\u00e1s:<\/strong> <a href=\"https:\/\/www.krebsinformationsdienst.de\/fachkreise\/nachrichten\/detail\/update-car-t-zell-therapie\" target=\"_blank\" rel=\"noopener\">DKFZ R\u00e1kinform\u00e1ci\u00f3s Szolg\u00e1lat - Update CAR-T: Egys\u00e9ges k\u00e9relmez\u00e9si elj\u00e1r\u00e1s \u00e9s kedvezm\u00e9nymeg\u00e1llapod\u00e1sok<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Mivel egy CAR-T term\u00e9k t\u00f6bb sz\u00e1zezer eur\u00f3ba ker\u00fcl, a klinik\u00e1knak k\u00f6lts\u00e9gt\u00e9r\u00edt\u00e9st kell szerezni\u00fck, miel\u0151tt elkezdhetik a ter\u00e1pi\u00e1t. Dr. Veit B\u00fccklein, a m\u00fcncheni LMU Klinikum vezet\u0151 orvosa \u00edgy \u00edrja le az ezzel j\u00e1r\u00f3 er\u0151fesz\u00edt\u00e9seket: \u201eKi kell t\u00f6lten\u00fcnk egy ellen\u0151rz\u0151 list\u00e1t, \u00e9s sok-sok dokumentumot kell \u00f6ssze\u00e1ll\u00edtanunk, A-t\u00f3l az orvos level\u00e9ig, Z-ig, az \u00f6sszes lelet \u00f6ssze\u00e1ll\u00edt\u00e1s\u00e1ig\u201c. A hivatalos elj\u00e1r\u00e1s neve \u201eegy\u00e9ni k\u00f6lts\u00e9gt\u00e9r\u00edt\u00e9si k\u00e9relmez\u00e9si elj\u00e1r\u00e1s\u201c.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forr\u00e1s:<\/strong> <a href=\"https:\/\/pharma-fakten.de\/news\/car-t-zelltherapie-zukunftsversprechen-versus-burokratiemonster\/\" target=\"_blank\" rel=\"noopener\">Gy\u00f3gyszer\u00e9szeti t\u00e9nyek - CAR-T: A j\u00f6v\u0151 \u00edg\u00e9rete kontra b\u00fcrokr\u00e1cia-sz\u00f6rnyeteg (LMU Klinikum M\u00fcnchen, 2024. szeptember)<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Prof. Dr. Marion Subklewe, az LMU Klinikum M\u00fcnchen CAR-T programj\u00e1nak vezet\u0151je \u00edgy foglalja \u00f6ssze a kritik\u00e1t: \u201eMi j\u00f3v\u00e1hagyott term\u00e9kekkel dolgozunk. Nem \u00e9rtem, mi\u00e9rt kell minden alkalommal egyedi k\u00e9relmet beny\u00fajtani egy enged\u00e9lyezett term\u00e9kre\u201c. A k\u00f6lts\u00e9gt\u00e9r\u00edt\u00e9si elj\u00e1r\u00e1sok jelenleg \u201eaz el\u0151rehalad\u00e1st megnehez\u00edt\u0151 eszk\u00f6z\u201c.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forr\u00e1s:<\/strong> <a href=\"https:\/\/pharma-fakten.de\/news\/car-t-zelltherapien-optimale-versorgung-sieht-anders-aus\/\" target=\"_blank\" rel=\"noopener\">Gy\u00f3gyszer\u00e9szeti t\u00e9nyek - CAR-T: az optim\u00e1lis ell\u00e1t\u00e1s m\u00e1sk\u00e9pp n\u00e9z ki (2025. \u00e1prilis)<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Prof. Dr. Michael Hallek, a k\u00f6lni egyetemi klinika I. Belgy\u00f3gy\u00e1szati Klinik\u00e1j\u00e1nak igazgat\u00f3ja szerint a megold\u00e1s az lenne, ha a CAR-T-sejtes ter\u00e1pi\u00e1kat szisztematikusan olyan szakosodott k\u00f6zpontokhoz rendeln\u00e9k, amelyek dokument\u00e1lj\u00e1k munk\u00e1jukat \u00e9s bizony\u00edtottan sikeresek, majd ezeknek a k\u00f6zpontoknak szabad kezet adn\u00e1nak a kezel\u00e9si d\u00f6nt\u00e9sek meghozatal\u00e1ban: \u201eAkkor elfelejthetn\u00e9nk a fel\u00fclvizsg\u00e1lati elj\u00e1r\u00e1st, mert ki m\u00e1snak kellene meg\u00edt\u00e9lnie, hogy egy kezel\u00e9s helyes-e vagy sem?\u201c.\u201c<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forr\u00e1s:<\/strong> <a href=\"https:\/\/pharma-fakten.de\/news\/car-t-zelltherapie-woran-es-noch-fehlt\/\" target=\"_blank\" rel=\"noopener\">Gy\u00f3gyszer\u00e9szeti t\u00e9nyek - CAR-T: Mi hi\u00e1nyzik m\u00e9g (rendezv\u00e9ny: K\u00f6lni Egyetemi K\u00f3rh\u00e1z, 2025. j\u00falius)<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Az egyetemi k\u00f3rh\u00e1zak szempontj\u00e1b\u00f3l a f\u0151 struktur\u00e1lis probl\u00e9ma az, hogy a jogalkot\u00f3 nem z\u00e1rta le a gy\u00f3gyszer enged\u00e9lyez\u00e9se \u00e9s a k\u00f3rh\u00e1zak garant\u00e1lt visszat\u00e9r\u00edt\u00e9si jogosults\u00e1ga k\u00f6z\u00f6tti id\u0151beli szakad\u00e9kot. Az \u00faj sejt- \u00e9s g\u00e9nter\u00e1pi\u00e1k eset\u00e9ben a k\u00f3rh\u00e1zak sz\u00e1m\u00e1ra t\u00fal nagy a p\u00e9nz\u00fcgyi kock\u00e1zat ahhoz, hogy el\u0151leget tudjanak fizetni.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forr\u00e1s:<\/strong> <a href=\"https:\/\/www.uniklinika.de\/gesundheitspolitischethemen\/car-t-zelltherapie\/\" target=\"_blank\" rel=\"noopener\">Uniklinika.de - CAR-T sejtter\u00e1pia: a visszat\u00e9r\u00edt\u00e9si biztons\u00e1g ir\u00e1nti ig\u00e9ny<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">E k\u00e9sedelmek orvosi k\u00f6vetkezm\u00e9nyei m\u00e9rhet\u0151ek: a CAR-T sejtter\u00e1pi\u00e1ra val\u00f3 egy h\u00f3napos v\u00e1rakoz\u00e1s 6,2 sz\u00e1zal\u00e9kkal n\u00f6velheti a relat\u00edv hal\u00e1loz\u00e1st. A CAR-T-hozz\u00e1f\u00e9r\u00e9s k\u00e9sedelme k\u00f6zvetlen hat\u00e1ssal lehet a kezel\u00e9s siker\u00e9re.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forr\u00e1s:<\/strong> <a href=\"https:\/\/pharma-fakten.de\/news\/car-t-zelltherapien-optimale-versorgung-sieht-anders-aus\/\" target=\"_blank\" rel=\"noopener\">Pharma-Fakten \/ IQVIA Institute - CAR-T: Az optim\u00e1lis ell\u00e1t\u00e1s m\u00e1sk\u00e9pp n\u00e9z ki (az IQVIA tanulm\u00e1ny\u00e1ra hivatkozva)<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ezenk\u00edv\u00fcl van egy m\u00e1sik struktur\u00e1lis probl\u00e9ma is: t\u00f6bb mint 160 k\u00f3rh\u00e1z ny\u00fajtott be NUB-k\u00e9relmet, hogy CAR-T ter\u00e1pi\u00e1kat k\u00edn\u00e1lhasson - de eredetileg csak 4-es NUB-st\u00e1tuszt kaptak, ami azt jelenti, hogy az eg\u00e9szs\u00e9gbiztos\u00edt\u00e1si p\u00e9nzt\u00e1r nem k\u00f6teles a k\u00f6lts\u00e9geket a NUB-meg\u00e1llapod\u00e1sok r\u00e9szek\u00e9nt fedezni.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forr\u00e1s:<\/strong> <a href=\"https:\/\/www.vdek.com\/magazin\/ausgaben\/2018-1112\/politik_car_t_zelltherapie.html\" target=\"_blank\" rel=\"noopener\">VDEK - Forradalom az onkol\u00f3gi\u00e1ban: NUB-st\u00e1tusz \u00e9s a CAR-T t\u00e9r\u00edt\u00e9si k\u00e9rd\u00e9sei<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Prof. Subklewe egy k\u00fcl\u00f6n\u00f6sen abszurd egy\u00e9ni p\u00e9ld\u00e1t \u00edr le a mindennapi k\u00f3rh\u00e1zi \u00e9letb\u0151l: \u201eNekem azt kell mondanom, hogy egy gasztroenterol\u00f3gusnak a nap 24 \u00f3r\u00e1j\u00e1ban a k\u00f6zelben kell lennie, holott az elm\u00falt \u00f6t \u00e9vben soha nem volt sz\u00fcks\u00e9gem r\u00e1\u201c.\u201c<br>B\u00e1r bizonyos min\u0151s\u00e9gi \u00e9s struktur\u00e1lis k\u00f6vetelm\u00e9nyeknek van \u00e9rtelme, nem szabad hagyni, hogy a jelenlegi m\u00f3don elszabaduljanak.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forr\u00e1s:<\/strong> <a href=\"https:\/\/pharma-fakten.de\/news\/car-t-zelltherapie-zukunftsversprechen-versus-burokratiemonster\/\" target=\"_blank\" rel=\"noopener\">Gy\u00f3gyszer\u00e9szeti t\u00e9nyek - CAR-T: a j\u00f6v\u0151 \u00edg\u00e9rete kontra b\u00fcrokr\u00e1cia sz\u00f6rnyeteg<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>A n\u00e9metorsz\u00e1gi min\u0151s\u00edtett CAR-T k\u00f6zpontok \u00e1ttekint\u00e9se<\/strong> (a betegek \u00e9s a beutal\u00f3 orvosok sz\u00e1m\u00e1ra):<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/www.novartis.com\/de-de\/uebersicht-behandelnder-car-t-zentren-deutschland\" target=\"_blank\" rel=\"noopener\">Novartis - A n\u00e9metorsz\u00e1gi CAR-T kezel\u0151k\u00f6zpontok \u00e1ttekint\u00e9se (Kymriah)<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.lmu-klinikum.de\/aktuelles\/pressemitteilungen\/funf-jahre-car-t-zelltherapie-am-lmu-klinikum-nbsp\/c52167393f8351f2\" target=\"_blank\" rel=\"noopener\">LMU Klinikum M\u00fcnchen - A CAR-T \u00f6t \u00e9ve: program \u00e9s kapcsolatfelv\u00e9tel<\/a> <\/li>\n\n\n\n<li><a href=\"https:\/\/www.dkfz.de\/de\/presse\/pressemitteilungen\/2020\/dkfz-pm-20-40-CAR-T-Zell-Therapien-erhebliche-Kostenersparnis-moeglich.php\" target=\"_blank\" rel=\"noopener\">DKFZ - CAR T-sejt ter\u00e1pia: k\u00f6lts\u00e9gmegtakar\u00edt\u00e1s a saj\u00e1t gy\u00e1rt\u00e1ssal<\/a><\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Das_%E2%80%9EPay-for-Outcome%E2%80%9C-Modell\"><\/span>A \u201efizet\u00e9s az eredm\u00e9ny\u00e9rt\u201c modell<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"> (teljes\u00edtm\u00e9nyhez k\u00f6t\u00f6tt visszat\u00e9r\u00edt\u00e9s)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Innovat\u00edv \u00e1tmeneti megold\u00e1sk\u00e9nt az egy\u00e9ni eg\u00e9szs\u00e9gbiztos\u00edt\u00e1si p\u00e9nzt\u00e1rak meg\u00e1llapodtak az \u00fan. <strong>Teljes\u00edtm\u00e9nyalap\u00fa szerz\u0151d\u00e9sek<\/strong> z\u00e1rva:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A Novartis \u00e9s a GWQ ServicePlus teljes\u00edtm\u00e9nyalap\u00fa t\u00e9r\u00edt\u00e9si modellt k\u00f6t\u00f6tt a Kymriah-ra vonatkoz\u00f3an, amely az els\u0151 ilyen jelleg\u0171 meg\u00e1llapod\u00e1s N\u00e9metorsz\u00e1gban:<br>A Novartis megt\u00e9r\u00edti a gy\u00f3gyszerk\u00f6lts\u00e9gek egy r\u00e9sz\u00e9t, ha a beteg a kezel\u00e9st k\u00f6vet\u0151 meghat\u00e1rozott id\u0151n bel\u00fcl meghal v\u00e9rr\u00e1kban. <br>A kimeneti param\u00e9ter a kezelt beteg t\u00fal\u00e9l\u00e9se.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ez a modell precedenst teremtett: a Techniker Krankenkasse \u00e9s m\u00e1s helyettes\u00edt\u0151 eg\u00e9szs\u00e9gbiztos\u00edt\u00e1si p\u00e9nzt\u00e1rak hasonl\u00f3 meg\u00e1llapod\u00e1sokkal k\u00f6vett\u00e9k a p\u00e9ld\u00e1t.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Welche_CAR-T-Produkte_sind_in_Deutschland_erstattungsfahig\"><\/span>Mely CAR-T term\u00e9kek jogosultak visszat\u00e9r\u00edt\u00e9sre N\u00e9metorsz\u00e1gban?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Term\u00e9k<\/th><th>Jelz\u00e9s<\/th><th>GKV st\u00e1tusz<\/th><\/tr><\/thead><tbody><tr><td><strong>Kymriah<\/strong> (Tisagenlecleucel)<\/td><td>B-ALL gyermek, DLBCL, FL<\/td><td>\u2705 T\u00e1rgyalt visszat\u00e9r\u00edt\u00e9si \u00f6sszeg (2019 szeptember\u00e9t\u0151l)<\/td><\/tr><tr><td><strong>Yescarta<\/strong> (Axicabtagene-cel)<\/td><td>DLBCL, PMBCL, FL, tFL<\/td><td>\u2705 T\u00e1rgyalt visszat\u00e9r\u00edt\u00e9si \u00f6sszeg<\/td><\/tr><tr><td><strong>Tecartus<\/strong> (Brexucabtagene-cel)<\/td><td>MCL, feln\u0151tt B-ALL<\/td><td>EMA-enged\u00e9lyezve; NUB-elj\u00e1r\u00e1s folyamatban\/befejezve<\/td><\/tr><tr><td><strong>Breyanzi<\/strong> (Lisocabtagene-cel)<\/td><td>DLBCL, CLL, FL<\/td><td>EMA-enged\u00e9lyezve; NUB-elj\u00e1r\u00e1s<\/td><\/tr><tr><td><strong>Abecma<\/strong> (Idecabtagene-cel)<\/td><td>Myeloma multiplex<\/td><td>EMA-enged\u00e9lyezve; NUB-elj\u00e1r\u00e1s<\/td><\/tr><tr><td><strong>Carvykti<\/strong> (Ciltacabtagene-cel)<\/td><td>Myeloma multiplex<\/td><td>EMA-enged\u00e9lyezve; NUB-elj\u00e1r\u00e1s<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Gyakorlati el\u0151felt\u00e9tel minden esetben<\/strong><br>A kezel\u0151k\u00f6zpontnak<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>teljes\u00edti a G-BA ATMP min\u0151s\u00e9gbiztos\u00edt\u00e1si ir\u00e1nymutat\u00e1s\u00e1t<\/li>\n\n\n\n<li>FACT\/JACIE akkredit\u00e1lt<\/li>\n\n\n\n<li>\u00e9s CAR-T k\u00f6zpontk\u00e9nt kell min\u0151s\u00edteni.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Csak ezut\u00e1n lehet meg\u00e1llapodni a NUB-d\u00edjakr\u00f3l \u00e9s kisz\u00e1ml\u00e1zni azokat.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Kimmtrak_Tebentafusp_%E2%80%93_Sonderfall\"><\/span>Kimmtrak (Tebentafusp) - k\u00fcl\u00f6nleges eset<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">A Kimmtrak nem egy cellaterm\u00e9k, hanem egy <strong>Biofarm\u00e1ciai<\/strong> \u00e9s a t\u00f6bbi r\u00e1kgy\u00f3gyszerhez hasonl\u00f3an a szok\u00e1sos AMNOG-elj\u00e1r\u00e1s al\u00e1 tartozik. Ambul\u00e1nsan adj\u00e1k be, \u00e9s \u00e1ltal\u00e1ban a szok\u00e1sos onkol\u00f3giai sz\u00e1ml\u00e1z\u00e1si m\u00f3dokon kereszt\u00fcl t\u00e9r\u00edthet\u0151, de csak a j\u00f3v\u00e1hagyott javallatra (<strong>HLA-A*02:01-pozit\u00edv uve\u00e1lis melanoma<\/strong>, els\u0151 sor).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"TIL-Therapie_Lifileucel_Amtagvi_%E2%80%93_In_Deutschland_derzeit_NICHT_erstattungsfahig\"><\/span>TIL-ter\u00e1pia (Lifileucel \/ Amtagvi) - N\u00e9metorsz\u00e1gban jelenleg NEM t\u00e9r\u00edthet\u0151 meg<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Ez a legfontosabb jelenlegi k\u00fcl\u00f6nbs\u00e9g az USA-hoz k\u00e9pest.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A v\u00e1llalat <em>Iovance<\/em> 2025. j\u00falius 22-\u00e9n visszavonta az EMA-hoz beny\u00fajtott forgalomba hozatali enged\u00e9ly ir\u00e1nti k\u00e9relm\u00e9t. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Az EMA-nak agg\u00e1lyai voltak a f\u0151 vizsg\u00e1latban a v\u00e1laszad\u00e1si ar\u00e1nyt illet\u0151en, valamint komoly biztons\u00e1gi agg\u00e1lyok mer\u00fcltek fel, egyes esetekben a ter\u00e1pia hal\u00e1lesetekkel j\u00e1rt.<br>Ezenk\u00edv\u00fcl a gy\u00e1rt\u00f3 nem rendelkezett megfelel\u0151 GMP-dokument\u00e1ci\u00f3val. <a href=\"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2025.43.16_suppl.TPS2673\" target=\"_blank\" rel=\"noreferrer noopener\">Amerikai Klinikai Onkol\u00f3giai T\u00e1rsas\u00e1g<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Az Iovance jelenleg az EMA-val k\u00f6z\u00f6sen \u00faj strat\u00e9gi\u00e1t dolgoz ki az Amtagvi uni\u00f3s forgalomba hozatali enged\u00e9ly\u00e9nek megszerz\u00e9s\u00e9re. Az Egyes\u00fclt Kir\u00e1lys\u00e1gban a j\u00f3v\u00e1hagy\u00e1s 2026 els\u0151 fel\u00e9ben v\u00e1rhat\u00f3; Ausztr\u00e1li\u00e1ban a priorit\u00e1si fel\u00fclvizsg\u00e1lat megt\u00f6rt\u00e9nt. <a href=\"https:\/\/www.globenewswire.com\/de\/news-release\/2025\/03\/27\/3050384\/0\/en\/Immatics-Announces-Full-Year-2024-Financial-Results-and-Business-Update.html\" target=\"_blank\" rel=\"noreferrer noopener\">GlobeNewswire<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>K\u00f6vetkeztet\u00e9s N\u00e9metorsz\u00e1g sz\u00e1m\u00e1ra:<\/strong> A Lifileucel jelenleg az EU-ban kaphat\u00f3 <strong>Nem enged\u00e9lyezett \u00e9s nem visszat\u00e9r\u00edtend\u0151<\/strong>. Azoknak a betegeknek, akik ezt a ter\u00e1pi\u00e1t ig\u00e9nylik, jelenleg az USA-ban kell r\u00e9szes\u00fclni\u00fck benne, saj\u00e1t k\u00f6lts\u00e9g\u00fck\u00f6n vagy klinikai vizsg\u00e1latok keret\u00e9ben.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"TCR-T-Therapien_Afami-cel_Tecelra_%E2%80%93_In_Europa_nicht_zugelassen\"><\/span>TCR-T ter\u00e1pi\u00e1k (Afami-cel \/ Tecelra) - Eur\u00f3p\u00e1ban nem enged\u00e9lyezett.<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Afamitresgene autoleucel (Tecelra) jelenleg <strong>csak az USA-ban enged\u00e9lyezett<\/strong> (FDA, 2024. augusztus). EMA-k\u00e9relmet m\u00e9g nem ny\u00fajtottak be.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ez\u00e9rt N\u00e9metorsz\u00e1gra a k\u00f6vetkez\u0151 vonatkozik: nincs k\u00f6lts\u00e9gt\u00e9r\u00edt\u00e9s, nincs rendszeres hozz\u00e1f\u00e9r\u00e9s, csak klinikai vizsg\u00e1latokon vagy egyedi ter\u00e1pi\u00e1s k\u00eds\u00e9rleteken kereszt\u00fcl (mint a Mailo eset\u00e9ben a heidelbergi KiTZ-ben).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Was_tun_wenn_die_Kasse_ablehnt_Rechtliche_Moglichkeiten\"><\/span>Mi a teend\u0151, ha a biztos\u00edt\u00f3 elutas\u00edtja? Jogi lehet\u0151s\u00e9gek<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Ha egy eg\u00e9szs\u00e9gbiztos\u00edt\u00e1si p\u00e9nzt\u00e1r elutas\u00edtja az EMA \u00e1ltal enged\u00e9lyezett ter\u00e1pia k\u00f6lts\u00e9geinek fedez\u00e9s\u00e9t, a k\u00f6vetkez\u0151 lehet\u0151s\u00e9gek \u00e1llnak rendelkez\u00e9sre:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Tiltakoz\u00e1s (SGB V 78. \u00a7)<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Az elutas\u00edt\u00e1st\u00f3l sz\u00e1m\u00edtott 4 h\u00e9ten bel\u00fcl \u00edr\u00e1sban ny\u00fajtson be kifog\u00e1st.<\/li>\n\n\n\n<li>A klinik\u00e1nak \u00e9s az orvosnak r\u00e9szletes orvosi jelent\u00e9st kell mell\u00e9kelnie.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Szoci\u00e1lis b\u00edr\u00f3s\u00e1gi kereset<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Ha a hat\u00e1rozat tov\u00e1bbra is elutas\u00edt\u00f3, ny\u00fajtson be panaszt az illet\u00e9kes szoci\u00e1lis b\u00edr\u00f3s\u00e1ghoz.<\/li>\n\n\n\n<li>\u00c9letvesz\u00e9lyes betegs\u00e9gek eset\u00e9n a <strong>\u00e1tmeneti jogv\u00e9delem<\/strong> k\u00e9relmezhet\u0151, <br>a b\u00edr\u00f3s\u00e1g ideiglenesen elrendelheti a k\u00f6lts\u00e9gek \u00e1tv\u00e1llal\u00e1s\u00e1t.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00a7 2. szakasz (1a) SGB V (Nikolaus-hat\u00e1rozat)<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u00c9letvesz\u00e9lyes betegs\u00e9g \u00e9s a szok\u00e1sos ter\u00e1pia hi\u00e1nya eset\u00e9n a biztos\u00edtottak jogosultak a nem szok\u00e1sos, enged\u00e9lyezett ter\u00e1pi\u00e1ra, ha komoly kil\u00e1t\u00e1s van a gy\u00f3gyul\u00e1sra vagy \u00e9rezhet\u0151 enyh\u00fcl\u00e9sre. Ez a k\u00f6zponti jogi eszk\u00f6z az olyan esetekre, mint az egy\u00e9ni kezel\u00e9si k\u00eds\u00e9rletek.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Fontos forr\u00e1sok:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/www.g-ba.de\/themen\/arzneimittel\/arzneimittel-richtlinie-anlagen\/nutzenbewertung-131e\/\" target=\"_blank\" rel=\"noopener\">Az immunsejtter\u00e1pi\u00e1k G-BA el\u0151nyeinek \u00e9rt\u00e9kel\u00e9se<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.dgho.de\/arbeitskreise\/a-g\/drg-gesundheitsoekonomie\/nub-2025\/nub-2025\" target=\"_blank\" rel=\"noopener\">DGHO NUB sablonok 2025<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.krebsinformationsdienst.de\/fachkreise\/nachrichten\/detail\/update-car-t-zell-therapie\" target=\"_blank\" rel=\"noopener\">DKFZ R\u00e1kinform\u00e1ci\u00f3s Szolg\u00e1lat - CAR-T \u00e9s GKV<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/pharma-fakten.de\/news\/car-t-zelltherapie-woran-es-noch-fehlt\/\" target=\"_blank\" rel=\"noopener\">Gy\u00f3gyszer\u00e9szeti t\u00e9nyek: CAR-T<\/a><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Osterreich\"><\/span>Ausztria<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Ausztria:<\/strong> A CAR-T sejtter\u00e1pia 2020. janu\u00e1r 1-j\u00e9n ker\u00fclt be az LKF szolg\u00e1ltat\u00e1si katal\u00f3gus\u00e1ba Ausztri\u00e1ban (MEL22.30 csoport: \u201eM\u00f3dos\u00edtott sejtek bead\u00e1sa\u201c) - \u00edgy kor\u00e1bban \u00e9s egy\u00e9rtelm\u0171bben szab\u00e1lyozott, mint N\u00e9metorsz\u00e1gban. <a href=\"https:\/\/www.clinicaltrialvanguard.com\/news\/t-knife-files-for-phase-1-trial-of-prame-t-cell-therapy\/\" target=\"_blank\" rel=\"noreferrer noopener\">Clinicaltrialvanguard<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Schweiz\"><\/span>Sv\u00e1jc<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Sv\u00e1jc:<\/strong> A KVG-n (eg\u00e9szs\u00e9gbiztos\u00edt\u00e1si t\u00f6rv\u00e9ny) kereszt\u00fcl t\u00f6rt\u00e9n\u0151 k\u00f6lts\u00e9gt\u00e9r\u00edt\u00e9s a B\u00c1PH szakter\u00fcleti list\u00e1j\u00e1ra val\u00f3 felv\u00e9tel ut\u00e1n; az EMA \u00e1ltal j\u00f3v\u00e1hagyott CAR-T term\u00e9kek eset\u00e9ben elvileg lehets\u00e9ges, egyedi eset\u00e9rt\u00e9kel\u00e9ssel is.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Zusammenfassung\"><\/span>\u00d6sszefoglal\u00f3<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Ter\u00e1pia<\/th><th>EU-s enged\u00e9lyez\u00e9s<\/th><th>SHI visszat\u00e9r\u00edt\u00e9s N\u00e9metorsz\u00e1g<\/th><\/tr><\/thead><tbody><tr><td>CAR-T (Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, Carvykti)<\/td><td>Igen (EMA)<\/td><td>Alapvet\u0151en igen - de egyedi k\u00e9relemmel\/NUB-on kereszt\u00fcl, jelent\u0151s b\u00fcrokr\u00e1ci\u00e1val.<\/td><\/tr><tr><td>Kimmtrak (Tebentafusp)<\/td><td>Igen (EMA)<\/td><td>Igen (AMNOG elj\u00e1r\u00e1s, ambul\u00e1nsan)<\/td><\/tr><tr><td>Lifileucel \/ Amtagvi (TIL)<\/td><td>Nem (2025 j\u00falius\u00e1ban visszavont EMA-k\u00e9relem)<\/td><td>Nem<\/td><\/tr><tr><td>Afami-cel \/ Tecelra (TCR-T)<\/td><td>Nem (csak FDA)<\/td><td>Nem<\/td><\/tr><tr><td>PRAME-TCR (IMA203, k\u00eds\u00e9rleti)<\/td><td>Nem (3. f\u00e1zis)<\/td><td>Nem - csak a tanulm\u00e1nyban val\u00f3 r\u00e9szv\u00e9tel r\u00e9v\u00e9n<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">A k\u00f6zponti politikai probl\u00e9ma tov\u00e1bbra is fenn\u00e1ll: A mai napig nincs igaz\u00e1n j\u00f3 jogi \u00e9s finansz\u00edroz\u00e1si keret ahhoz, hogy ezek az innovat\u00edv ter\u00e1pi\u00e1k gyorsan \u00e9s megb\u00edzhat\u00f3an megjelenjenek a n\u00e9met rendszerben. \u00c9vekbe telhet, mire egy orvosi innov\u00e1ci\u00f3 k\u00f6lts\u00e9gei megfelel\u0151en megjelennek az esetenk\u00e9nti \u00e1tal\u00e1nyrendszerben.<\/p>\n\n\n\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"PKV_und_Immunzelltherapie_%E2%80%93_Die_vollstandige_Rechtslage\"><\/span>PKV \u00e9s immunsejtter\u00e1pia - a teljes jogi helyzet<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">\u00c1llapot: 2026. febru\u00e1r<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Das_rechtliche_Fundament_%C2%A7_192_VVG_und_MBKK_2009\"><\/span>A jogalap: VVG 192. \u00a7 \u00e9s MB\/KK 2009<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">A gy\u00f3gyszerk\u00f6lts\u00e9g-biztos\u00edt\u00e1s eset\u00e9ben a biztos\u00edt\u00f3 k\u00f6teles a betegs\u00e9g vagy baleset k\u00f6vetkezm\u00e9nyei miatt orvosilag sz\u00fcks\u00e9ges kezel\u00e9s k\u00f6lts\u00e9geit a meg\u00e1llapod\u00e1s szerinti m\u00e9rt\u00e9kben megt\u00e9r\u00edteni. A biztos\u00edt\u00f3 nem k\u00f6teles ell\u00e1t\u00e1st fizetni, ha az orvosi kezel\u00e9s vagy egy\u00e9b ell\u00e1t\u00e1s k\u00f6lts\u00e9gei szembet\u0171n\u0151en ar\u00e1nytalanok a ny\u00fajtott ell\u00e1t\u00e1shoz k\u00e9pest.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Jogi megfogalmaz\u00e1s VVG 192. \u00a7 (teljes):<\/strong> <a href=\"https:\/\/dejure.org\/gesetze\/VVG\/192.html\" target=\"_blank\" rel=\"noopener\">dejure.org - VVG 192. szakasz A biztos\u00edt\u00f3 tipikus szerz\u0151d\u00e9ses juttat\u00e1sai<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Hivatalos mintafelt\u00e9telek MB\/KK 2009 (PDF, PKV-Verband):<\/strong> <a href=\"https:\/\/www.pkv.de\/fileadmin\/user_upload\/PKV\/3_PDFs\/ABV_und_MB\/MB-KK.pdf\" target=\"_blank\" rel=\"noopener\">pkv.de - MB\/KK 2009 mintafelt\u00e9telek<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A mag\u00e1n-eg\u00e9szs\u00e9gbiztos\u00edt\u00f3k ell\u00e1t\u00e1si k\u00f6telezetts\u00e9g\u00e9t alapvet\u0151en az adott esetben v\u00e1lasztott tarifa \u00e9s a kapcsol\u00f3d\u00f3 tarifak\u00f6r\u00fclm\u00e9nyek hat\u00e1rozz\u00e1k meg. A VVG 192. \u00a7 (1) bekezd\u00e9se szerint, \u00f6sszef\u00fcgg\u00e9sben az MB\/KK-val, a betegs\u00e9g vagy baleset k\u00f6vetkezm\u00e9nyei miatt orvosilag sz\u00fcks\u00e9ges gy\u00f3gykezel\u00e9s k\u00f6lts\u00e9gei megt\u00e9r\u00fclnek.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>A VVG 192. \u00a7 szerinti PKV-ell\u00e1t\u00e1si k\u00f6telezetts\u00e9g magyar\u00e1zata:<\/strong> <a href=\"https:\/\/www.legal-plus.eu\/die-leistungspflicht-der-privaten-krankenversicherung-pkv-wann-und-wofuer-muss-die-pkv-zahlen\/\" target=\"_blank\" rel=\"noopener\">legal-plus.eu - A PKV fizet\u00e9si k\u00f6telezetts\u00e9ge: Mikor \u00e9s mi\u00e9rt kell a PKV-nak fizetnie?<\/a><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Der_Schlusselbegriff_%E2%80%9EMedizinisch_notwendige_Heilbehandlung%E2%80%9C\"><\/span>A kulcssz\u00f3: \u201eorvosilag sz\u00fcks\u00e9ges kezel\u00e9s\u201c.\u201c<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">A kialakult \u00edt\u00e9lkez\u00e9si gyakorlat szerint, valamint az MB\/KK \u00e9s a VVG 192. \u00a7-\u00e1nak mintafelt\u00e9teleivel \u00f6sszhangban az orvosi sz\u00fcks\u00e9gess\u00e9g akkor \u00e1ll fenn, ha a kezel\u00e9s az objekt\u00edv orvosi meg\u00e1llap\u00edt\u00e1sok \u00e9s ismeretek szerint alkalmas a betegs\u00e9g felismer\u00e9s\u00e9re \u00e9s gy\u00f3gy\u00edt\u00e1s\u00e1ra, s\u00falyosbod\u00e1s\u00e1nak megel\u0151z\u00e9s\u00e9re vagy a t\u00fcnetek enyh\u00edt\u00e9s\u00e9re. A d\u00f6nt\u0151 t\u00e9nyez\u0151 az, hogy a kezel\u00e9s id\u0151pontj\u00e1ban a hozz\u00e1\u00e9rt\u0151 orvos v\u00e9lem\u00e9nye szerint az int\u00e9zked\u00e9s az elismert tudom\u00e1nyos norm\u00e1k szerint sz\u00fcks\u00e9gesnek t\u0171nik.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Jogi elemz\u00e9s: Az orvosi sz\u00fcks\u00e9gess\u00e9g meghat\u00e1roz\u00e1sa a mag\u00e1n-eg\u00e9szs\u00e9gbiztos\u00edt\u00e1sban:<\/strong> <a href=\"https:\/\/kanzlei-neue-kraeme.de\/erstattung-kostenintensiver-behandlungsmassnahmen-in-der-pkv\/\" target=\"_blank\" rel=\"noopener\">kanzlei-neue-kraeme.de - A k\u00f6lts\u00e9gig\u00e9nyes kezel\u00e9sek visszat\u00e9r\u00edt\u00e9se a mag\u00e1n-eg\u00e9szs\u00e9gbiztos\u00edt\u00e1sban<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A hagyom\u00e1nyos orvosl\u00e1s \u00e1ltal elismert kezel\u00e9sek mellett a mag\u00e1n-eg\u00e9szs\u00e9gbiztos\u00edt\u00e1s olyan kezel\u00e9seket is megt\u00e9r\u00edt, amelyek a gyakorlatban hasonl\u00f3an \u00edg\u00e9retesnek bizonyultak, vagy amelyeknek nincs alternat\u00edv\u00e1ja. Ezek lehetnek \u00faj gy\u00f3gyszerek vagy a szak\u00e9rt\u0151k \u00e1ltal hasznosnak \u00edt\u00e9lt innovat\u00edv diagnosztikai elj\u00e1r\u00e1sok \u00e9s kezel\u00e9si m\u00f3dszerek is.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>PKV Sz\u00f6vets\u00e9g: Hivatalos magyar\u00e1zat az ell\u00e1t\u00e1sokr\u00f3l \u00e9s a k\u00f6lts\u00e9gt\u00e9r\u00edt\u00e9sr\u0151l (bele\u00e9rtve az innovat\u00edv ter\u00e1pi\u00e1kat):<\/strong> <a href=\"https:\/\/www.pkv.de\/wissen\/private-krankenversicherung\/leistungen-und-erstattung\/\" target=\"_blank\" rel=\"noopener\">pkv.de - Juttat\u00e1sok \u00e9s visszat\u00e9r\u00edt\u00e9s a mag\u00e1n eg\u00e9szs\u00e9gbiztos\u00edt\u00e1sban<\/a><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Das_Richtungsurteil_OLG_Frankfurt_29062022_%E2%80%93_Az_7_U_14021\"><\/span>A m\u00e9rf\u00f6ldk\u0151nek sz\u00e1m\u00edt\u00f3 \u00edt\u00e9let: OLG Frankfurt, 29.06.2022 - Ref. 7 U 140\/21.<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Ez az immunsejtter\u00e1pi\u00e1k n\u00e9metorsz\u00e1gi mag\u00e1n-eg\u00e9szs\u00e9gbiztos\u00edt\u00e1si t\u00e9r\u00edt\u00e9s\u00e9nek kulcsfontoss\u00e1g\u00fa d\u00f6nt\u00e9se.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Az \u00fcgy t\u00e9ny\u00e1ll\u00e1sa<\/strong><br>Egy betegn\u00e9l nem oper\u00e1lhat\u00f3 hasny\u00e1lmirigy-daganatot diagnosztiz\u00e1ltak. Miut\u00e1n a kemoter\u00e1pia sikertelen volt, a beteg a standard palliat\u00edv ter\u00e1pia ellen d\u00f6nt\u00f6tt, amely alacsonyabb sikeress\u00e9gi progn\u00f3zissal kecsegtetett, \u00e9s helyette a dendritikus sejtter\u00e1pi\u00e1t v\u00e1lasztotta. A k\u00f6lts\u00e9geket a mag\u00e1n-eg\u00e9szs\u00e9gbiztos\u00edt\u00f3t\u00f3l akarta visszak\u00f6vetelni - de az nem volt hajland\u00f3 teljes eg\u00e9sz\u00e9ben kifizetni.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00cdt\u00e9let<\/strong><br>A dendritikus sejtter\u00e1pia a mag\u00e1n eg\u00e9szs\u00e9gbiztos\u00edt\u00f3k gy\u00f3gyszerk\u00f6lts\u00e9gi felt\u00e9telei (MB\/KK 2009) \u00e9rtelm\u00e9ben gy\u00f3gykezel\u00e9snek min\u0151s\u00fcl. Ha egy \u00e9letvesz\u00e9lyes \u00e9s gy\u00f3gy\u00edthatatlan daganatban szenved\u0151 szem\u00e9ly eset\u00e9ben a hagyom\u00e1nyos els\u0151 vonalbeli ter\u00e1pia nem vezet a k\u00edv\u00e1nt kezel\u00e9si sikerhez, a biztos\u00edtottat nem kell a m\u00e9g rosszabb eredm\u00e9nyess\u00e9gi progn\u00f3zis\u00fa m\u00e1sodik vonalbeli ter\u00e1pi\u00e1ra utalni. Ink\u00e1bb k\u00e9rheti egy \u00faj, tudom\u00e1nyosan megalapozott alternat\u00edv ter\u00e1pia k\u00f6lts\u00e9geinek k\u00f6zvetlen kifizet\u00e9s\u00e9t, ha a kezel\u00e9s id\u0151pontj\u00e1ban ez a kezel\u00e9s a szok\u00e1sos palliat\u00edv ter\u00e1pi\u00e1n t\u00falmen\u0151en nem teljesen t\u00e1voli kil\u00e1t\u00e1st ny\u00fajt a siker el\u00e9r\u00e9s\u00e9re.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Az \u00edt\u00e9let teljes t\u00e1rgyal\u00e1sa (DATEV Magazin):<\/strong> <a href=\"https:\/\/www.datev-magazin.de\/nachrichten-steuern-recht\/recht\/private-krankenversicherung-muss-bei-inoperablem-tumor-nach-gescheiterter-chemotherapie-kosten-einer-alternativtherapie-mit-dendritischen-zellen-tragen-81762\" target=\"_blank\" rel=\"noopener\">datev-magazin.de - OLG Frankfurt: a PKV-nek viselnie kell a dendritikus sejtter\u00e1pia k\u00f6lts\u00e9geit<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Az \u00edt\u00e9let fel\u00fclvizsg\u00e1lata a joger\u0151 meger\u0151s\u00edt\u00e9s\u00e9vel (2023. janu\u00e1r):<\/strong> <a href=\"https:\/\/transkript.de\/artikel\/2023\/krankenkasse-muss-zelltherapie-zahlen\/\" target=\"_blank\" rel=\"noopener\">transkript.de - Az eg\u00e9szs\u00e9gbiztos\u00edt\u00f3nak fizetnie kell a sejtter\u00e1pi\u00e1\u00e9rt (bele\u00e9rtve a joger\u0151 meger\u0151s\u00edt\u00e9s\u00e9t)<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>K\u00f3rh\u00e1zakra vonatkoz\u00f3 \u00edt\u00e9letelemz\u00e9s (IWW Verg\u00fctungsrecht):<\/strong> <a href=\"https:\/\/www.iww.de\/cb\/recht\/verguetungsrecht-schulmedizinische-behandlung-erfolglos-pkvmuss-kosten-der-alternativtherapie-tragen-f149155\" target=\"_blank\" rel=\"noopener\">iww.de - A PKV-nek viselnie kell az alternat\u00edv ter\u00e1pia k\u00f6lts\u00e9geit<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Haufe: Az \u00edt\u00e9let r\u00f6vid \u00f6sszefoglal\u00e1sa:<\/strong> <a href=\"https:\/\/www.haufe.de\/recht\/weitere-rechtsgebiete\/inoperabler-tumor-uebernahme-von-alternativtherapie-durch-pkv_216_571650.html\" target=\"_blank\" rel=\"noopener\">haufe.de - Inoper\u00e1bilis tumor: Alternat\u00edv ter\u00e1pia a PKV \u00e1ltal fedezve<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>R\u00e9szletes \u00edt\u00e9letelemz\u00e9s (J\u00f6hnke &amp; Reichow Rechtsanw\u00e4lte):<\/strong> <a href=\"https:\/\/joehnke-reichow.de\/2024\/07\/17\/kostenerstattung-bei-einer-dendritischen-zellbehandlung-olg-frankfurt\/\" target=\"_blank\" rel=\"noopener\">joehnke-reichow.de - Dendritikus sejtes kezel\u00e9s k\u00f6lts\u00e9geinek megt\u00e9r\u00edt\u00e9se, OLG Frankfurt<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Joger\u0151:<\/strong> A hesseni fels\u0151b\u00edr\u00f3s\u00e1g szerint a fellebbez\u00e9s beny\u00fajt\u00e1s\u00e1nak hat\u00e1rideje lej\u00e1rt, \u00edgy a hat\u00e1rozat 2023 janu\u00e1rj\u00e1t\u00f3l joger\u0151s.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Das_%E2%80%9Eauffallige_Missverhaltnis%E2%80%9C_nach_%C2%A7_192_Abs_2_VVG_%E2%80%93_und_warum_es_bei_CAR-T_nicht_greift\"><\/span>A VVG 192. \u00a7 (2) bekezd\u00e9se szerinti \u201efelt\u0171n\u0151 ar\u00e1nytalans\u00e1g\u201c - \u00e9s hogy mi\u00e9rt nem vonatkozik a CAR-T-re<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">A felt\u0171n\u0151 ar\u00e1nytalans\u00e1g fenn\u00e1ll\u00e1s\u00e1nak bemutat\u00e1sa \u00e9s bizony\u00edt\u00e1sa a biztos\u00edt\u00f3t terheli. Egyet\u00e9rt\u00e9s van abban, hogy a ny\u00fajtott szolg\u00e1ltat\u00e1s szok\u00e1sos \u00e9rt\u00e9ke \u00e9s nem az orvosi minimumsz\u00ednvonal \u00e1ra a meghat\u00e1roz\u00f3. A Sz\u00f6vets\u00e9gi B\u00edr\u00f3s\u00e1g uzsor\u00e1s b\u0171ncselekm\u00e9nyekre vonatkoz\u00f3 \u00edt\u00e9lkez\u00e9si gyakorlat\u00e1t alkalmazva a piaci \u00f6sszehasonl\u00edt\u00e1s alkalmas eszk\u00f6z az objekt\u00edv \u00e9rt\u00e9k meghat\u00e1roz\u00e1s\u00e1ra.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Mivel a CAR-T ter\u00e1pi\u00e1k \u00e1ra vil\u00e1gszerte hasonl\u00f3 szinten mozog (250 000-600 000 eur\u00f3), a \u201eszembet\u0171n\u0151 egyens\u00falyhi\u00e1ny\u201c nemzetk\u00f6zi piaci \u00f6sszehasonl\u00edt\u00e1ssal \u00e9rv\u00e9nytelen\u00edthet\u0151.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>A VVG 192. \u00a7 (2) bekezd\u00e9se szerinti \u201efelt\u0171n\u0151 ar\u00e1nytalans\u00e1g\u201c jogi elemz\u00e9se:<\/strong> <a href=\"https:\/\/www.kunzrechtsanwaelte.de\/aktuelles\/urteile\/versicherung-und-haftung\/krankenversicherung\" target=\"_blank\" rel=\"noopener\">kunzrechtsanwaelte.de - A VVG 192. \u00a7 (2) bekezd\u00e9se szerinti felt\u0171n\u0151 ar\u00e1nytalans\u00e1gr\u00f3l<\/a><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Das_Voranfrageverfahren_nach_%C2%A7_192_Abs_8_VVG_%E2%80%93_der_wichtigste_praktische_Schritt\"><\/span>A VVG 192. \u00a7 (8) bekezd\u00e9se szerinti el\u0151zetes vizsg\u00e1lati elj\u00e1r\u00e1s - a legfontosabb gyakorlati l\u00e9p\u00e9s<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Amint el\u0151re l\u00e1that\u00f3, hogy a v\u00e1rhat\u00f3 kezel\u00e9si k\u00f6lts\u00e9gek meghaladj\u00e1k a 2000 eur\u00f3t, a biztos\u00edtott a VVG 192. \u00a7 (8) bekezd\u00e9se szerint jogosult a k\u00f6lts\u00e9gv\u00e1llal\u00e1sr\u00f3l sz\u00f3l\u00f3 t\u00e1j\u00e9koztat\u00e1sra. A k\u00f6lts\u00e9gbecsl\u00e9s beny\u00fajt\u00e1s\u00e1t\u00f3l sz\u00e1m\u00edtott 4 h\u00e9ten bel\u00fcl a biztos\u00edt\u00f3nak j\u00f3v\u00e1 kell hagynia vagy el kell utas\u00edtania a k\u00f6lts\u00e9g\u00e1tv\u00e1llal\u00e1st.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ha a t\u00e1j\u00e9koztat\u00e1s nem t\u00f6rt\u00e9nik meg a hat\u00e1rid\u0151n bel\u00fcl, a biztos\u00edt\u00f3 az ellenkez\u0151 bizony\u00edt\u00e1s\u00e1ig felt\u00e9telezi, hogy a tervezett orvosi kezel\u00e9s sz\u00fcks\u00e9ges. Ez a <strong>A sz\u00fcks\u00e9gszer\u0171s\u00e9g fikci\u00f3ja<\/strong> a v\u00e1laszad\u00e1s elmarad\u00e1sa eset\u00e9n fontos v\u00e9d\u0151eszk\u00f6z a betegek sz\u00e1m\u00e1ra.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>A VVG 192. \u00a7 (8) bekezd\u00e9s\u00e9nek sz\u00f6vege (el\u0151zetes t\u00e1j\u00e9koz\u00f3d\u00e1si k\u00f6telezetts\u00e9g):<\/strong> <a href=\"https:\/\/dejure.org\/gesetze\/VVG\/192.html\" target=\"_blank\" rel=\"noopener\">dejure.org - VVG 192. szakasz (8) bekezd\u00e9s<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Gyakorlati \u00fatmutat\u00f3: El\u0151zetes megkeres\u00e9s a PKV-n\u00e1l a k\u00f6lts\u00e9gig\u00e9nyes kezel\u00e9s el\u0151tt:<\/strong> <a href=\"https:\/\/www.pkv-inhalte.de\/pkv-bu-av-blog\/pkv-versichert-und-teure-behandlung-steht-bevor-wie-geht-man-richtig-vor\/\" target=\"_blank\" rel=\"noopener\">pkv-inhalte.de - PKV biztos\u00edt\u00e1s \u00e9s dr\u00e1ga kezel\u00e9s: Mi a helyes megk\u00f6zel\u00edt\u00e9s?<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>A helytelen vagy hi\u00e1nyz\u00f3 PKV-adatok jogi k\u00f6vetkezm\u00e9nyei:<\/strong> <a href=\"https:\/\/www.versicherungsrechtsiegen.de\/krankenhauskosten-zusatzversicherung-kostenerstattung-fuer-aufenthalt-in-privatklinik\/\" target=\"_blank\" rel=\"noopener\">versicherungsrechtsiegen.de - K\u00f6lts\u00e9gv\u00e1llal\u00e1s \u00e9s a VVG 192. \u00a7 (8) bekezd\u00e9se a gyakorlatban<\/a><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Bei_Ablehnung_Rechtsmittel_und_Klage\"><\/span>Elutas\u00edt\u00e1s eset\u00e9n: fellebbez\u00e9s \u00e9s jogi elj\u00e1r\u00e1s<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">A visszat\u00e9r\u00edt\u00e9s k\u00e9rd\u00e9s\u00e9t a VVG 192. \u00a7-a, az MB\/KK modellfelt\u00e9telek \u00e9s az egyes d\u00edjszab\u00e1si z\u00e1rad\u00e9kok k\u00f6lcs\u00f6nhat\u00e1sa hat\u00e1rozza meg. A d\u00f6nt\u0151 t\u00e9nyez\u0151 az, hogy a kezel\u00e9sre betegs\u00e9g miatt ker\u00fclt-e sor, \u00e9s hogy az orvosilag sz\u00fcks\u00e9ges volt-e.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A PKV elutas\u00edt\u00e1sa eset\u00e9n a k\u00f6vetkez\u0151 lehet\u0151s\u00e9gek \u00e1llnak rendelkez\u00e9sre:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Tiltakoz\u00e1s teljes orvosi dokument\u00e1ci\u00f3val<\/strong> (orvosi v\u00e9lem\u00e9ny, tumorbizotts\u00e1gi protokoll, nemzetk\u00f6zi vizsg\u00e1lati helyzet, k\u00f6lts\u00e9gbecsl\u00e9s)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Polg\u00e1ri peres elj\u00e1r\u00e1s<\/strong> (nem szoci\u00e1lis b\u00edr\u00f3s\u00e1g, ez a k\u00fcl\u00f6nbs\u00e9g a k\u00f6telez\u0151 eg\u00e9szs\u00e9gbiztos\u00edt\u00e1shoz k\u00e9pest), ideiglenes int\u00e9zked\u00e9s ir\u00e1nti k\u00e9relemmel, s\u00fcrg\u0151s kezel\u00e9si ig\u00e9ny eset\u00e9n.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Teljes \u00fatmutat\u00f3: PKV elutas\u00edt\u00e1s, kifog\u00e1s \u00e9s jogi elj\u00e1r\u00e1s:<\/strong> <a href=\"https:\/\/kanzlei-neue-kraeme.de\/erstattung-kostenintensiver-behandlungsmassnahmen-in-der-pkv\/\" target=\"_blank\" rel=\"noopener\">kanzlei-neue-kraeme.de - A k\u00f6lts\u00e9gig\u00e9nyes kezel\u00e9sek visszat\u00e9r\u00edt\u00e9se a mag\u00e1n-eg\u00e9szs\u00e9gbiztos\u00edt\u00e1s keret\u00e9ben<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>A mag\u00e1n-eg\u00e9szs\u00e9gbiztos\u00edt\u00e1s \u00e9s az ell\u00e1t\u00e1sok visszautas\u00edt\u00e1sa: jogi l\u00e9p\u00e9sek \u00e1ttekint\u00e9se:<\/strong> <a href=\"https:\/\/kva-plus.de\/ablehnung-der-kostenuebernahme-durch-die-pkv-und-beihilfe\/\" target=\"_blank\" rel=\"noopener\">kva-plus.de - A mag\u00e1n-eg\u00e9szs\u00e9gbiztos\u00edt\u00e1s \u00e1ltal ny\u00fajtott k\u00f6lts\u00e9gt\u00e9r\u00edt\u00e9s elutas\u00edt\u00e1sa \u00e9s \u00e1llami t\u00e1mogat\u00e1s<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p><span class=\"span-reading-time rt-reading-time\" style=\"display: block;\"><span class=\"rt-label rt-prefix\">Olvas\u00e1si id\u0151<\/span> <span class=\"rt-time\"> 20<\/span> <span class=\"rt-label rt-postfix\">percek<\/span><\/span>Das Immunsystem &#8211; was macht das? Das Immunsystem unterh\u00e4lt eine ganze Armee von Kundschaftern, K\u00e4mpfern (T-Zellen) und Helfern. Sie patrouillieren st\u00e4ndig durch den K\u00f6rper und suchen nach Eindringlingen, wie Bakterien, Viren, aber auch wild gewordene k\u00f6rpereigene Zellen &#8211; Krebszellen. Normalerweise werden solch randalierende Zellen von den W\u00e4chtern des immunsystems schnell entdeckt, abget\u00f6tet, deren \u00dcberreste abtransportiert&hellip;&nbsp;<a href=\"https:\/\/csiag.eu\/hu\/blog\/2026\/02\/19\/immunzelltherapie\/\" rel=\"bookmark\">Olvass tov\u00e1bb \"<span class=\"screen-reader-text\">Immunsejt-ter\u00e1pia<\/span><\/a><\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","footnotes":""},"categories":[5584,1078,354],"tags":[],"class_list":["post-12789","post","type-post","status-publish","format-standard","hentry","category-krebs","category-medizin","category-medizin-gesundheit"],"modified_by":"Achim Goerner","_links":{"self":[{"href":"https:\/\/csiag.eu\/hu\/wp-json\/wp\/v2\/posts\/12789","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/csiag.eu\/hu\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/csiag.eu\/hu\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/csiag.eu\/hu\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/csiag.eu\/hu\/wp-json\/wp\/v2\/comments?post=12789"}],"version-history":[{"count":0,"href":"https:\/\/csiag.eu\/hu\/wp-json\/wp\/v2\/posts\/12789\/revisions"}],"wp:attachment":[{"href":"https:\/\/csiag.eu\/hu\/wp-json\/wp\/v2\/media?parent=12789"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/csiag.eu\/hu\/wp-json\/wp\/v2\/categories?post=12789"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/csiag.eu\/hu\/wp-json\/wp\/v2\/tags?post=12789"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}